Stem definition | Drug id | CAS RN |
---|---|---|
52 | 103-90-2 |
Dose | Unit | Route |
---|---|---|
3 | g | O |
3 | g | P |
3 | g | R |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 23.70 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 3 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 330.76 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 88 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 1 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 5 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.52 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 2.50 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Nov. 7, 1968 | FDA | POLYMEDICA |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Toxicity to various agents | 2425.99 | 11.09 | 8014 | 775349 | 204485 | 49617276 |
Completed suicide | 1241.73 | 11.09 | 4672 | 778691 | 127217 | 49694544 |
Intentional overdose | 1165.29 | 11.09 | 2819 | 780544 | 59685 | 49762076 |
Acute hepatic failure | 1138.75 | 11.09 | 1308 | 782055 | 14369 | 49807392 |
Overdose | 1035.71 | 11.09 | 3648 | 779715 | 96079 | 49725682 |
Analgesic drug level increased | 874.69 | 11.09 | 460 | 782903 | 1271 | 49820490 |
Drug ineffective | 778.61 | 11.09 | 8535 | 774828 | 810798 | 49010963 |
Hepatocellular injury | 683.94 | 11.09 | 1346 | 782017 | 24601 | 49797160 |
Metabolic acidosis | 443.59 | 11.09 | 1467 | 781896 | 37358 | 49784403 |
Poisoning deliberate | 432.18 | 11.09 | 572 | 782791 | 7340 | 49814421 |
Suicide attempt | 404.68 | 11.09 | 1731 | 781632 | 50001 | 49771760 |
Injection site pain | 354.86 | 11.09 | 741 | 782622 | 110283 | 49711478 |
Product dose omission issue | 340.67 | 11.09 | 1574 | 781789 | 182264 | 49639497 |
Device expulsion | 305.02 | 11.09 | 42 | 783321 | 28780 | 49792981 |
Infusion related reaction | 302.38 | 11.09 | 3979 | 779384 | 165578 | 49656183 |
Intentional product misuse | 298.87 | 11.09 | 1474 | 781889 | 45260 | 49776501 |
Exposure to toxic agent | 292.60 | 11.09 | 321 | 783042 | 3337 | 49818424 |
Cholestasis | 291.20 | 11.09 | 961 | 782402 | 24440 | 49797321 |
Drug hypersensitivity | 256.01 | 11.09 | 2566 | 780797 | 248444 | 49573317 |
Hepatic failure | 242.29 | 11.09 | 1067 | 782296 | 31216 | 49790545 |
Off label use | 236.84 | 11.09 | 5567 | 777796 | 468859 | 49352902 |
Hepatotoxicity | 233.26 | 11.09 | 937 | 782426 | 26289 | 49795472 |
Alopecia | 229.99 | 11.09 | 2554 | 780809 | 242493 | 49579268 |
Injection site erythema | 227.90 | 11.09 | 514 | 782849 | 74422 | 49747339 |
Injection site reaction | 189.16 | 11.09 | 301 | 783062 | 49731 | 49772030 |
Coma | 172.45 | 11.09 | 1486 | 781877 | 55393 | 49766368 |
Coagulopathy | 169.55 | 11.09 | 637 | 782726 | 17307 | 49804454 |
Blood pressure fluctuation | 168.68 | 11.09 | 1040 | 782323 | 34783 | 49786978 |
Treatment failure | 168.67 | 11.09 | 1342 | 782021 | 136295 | 49685466 |
Drug resistance | 166.42 | 11.09 | 44 | 783319 | 18945 | 49802816 |
Anion gap | 165.86 | 11.09 | 139 | 783224 | 998 | 49820763 |
Somnolence | 160.48 | 11.09 | 3327 | 780036 | 151658 | 49670103 |
Therapeutic product effect incomplete | 152.96 | 11.09 | 812 | 782551 | 90703 | 49731058 |
Sinusitis | 152.74 | 11.09 | 3586 | 779777 | 166972 | 49654789 |
Cholecystitis chronic | 151.86 | 11.09 | 409 | 782954 | 9260 | 49812501 |
Hepatitis | 151.17 | 11.09 | 918 | 782445 | 30535 | 49791226 |
Wrong technique in product usage process | 150.53 | 11.09 | 404 | 782959 | 55106 | 49766655 |
Hospitalisation | 147.92 | 11.09 | 546 | 782817 | 67391 | 49754370 |
Lower respiratory tract infection | 147.20 | 11.09 | 2179 | 781184 | 93022 | 49728739 |
Abdominal discomfort | 147.07 | 11.09 | 2611 | 780752 | 229030 | 49592731 |
Confusional state | 138.75 | 11.09 | 3815 | 779548 | 182113 | 49639648 |
International normalised ratio increased | 135.87 | 11.09 | 1137 | 782226 | 42015 | 49779746 |
Systemic lupus erythematosus | 134.38 | 11.09 | 1459 | 781904 | 139163 | 49682598 |
Injection site swelling | 132.37 | 11.09 | 280 | 783083 | 41493 | 49780268 |
Injection site pruritus | 132.17 | 11.09 | 266 | 783097 | 40145 | 49781616 |
Accidental overdose | 129.80 | 11.09 | 623 | 782740 | 18910 | 49802851 |
Depressed level of consciousness | 129.17 | 11.09 | 1301 | 782062 | 50652 | 49771109 |
Psoriasis | 128.67 | 11.09 | 589 | 782774 | 68411 | 49753350 |
Folliculitis | 127.50 | 11.09 | 1041 | 782322 | 38184 | 49783577 |
Maternal exposure during pregnancy | 125.67 | 11.09 | 1729 | 781634 | 158049 | 49663712 |
Muscle injury | 121.22 | 11.09 | 986 | 782377 | 36125 | 49785636 |
Pemphigus | 120.80 | 11.09 | 1232 | 782131 | 118934 | 49702827 |
Body temperature increased | 115.85 | 11.09 | 857 | 782506 | 30484 | 49791277 |
Hepatitis acute | 114.39 | 11.09 | 326 | 783037 | 7635 | 49814126 |
Pyroglutamate increased | 112.47 | 11.09 | 74 | 783289 | 346 | 49821415 |
Injection site bruising | 111.10 | 11.09 | 253 | 783110 | 36515 | 49785246 |
Irritable bowel syndrome | 109.63 | 11.09 | 1249 | 782114 | 50192 | 49771569 |
Hepatic cytolysis | 108.92 | 11.09 | 324 | 783039 | 7779 | 49813982 |
Medication error | 106.68 | 11.09 | 938 | 782425 | 35166 | 49786595 |
Hepatitis fulminant | 106.00 | 11.09 | 179 | 783184 | 2889 | 49818872 |
Hepatic necrosis | 105.60 | 11.09 | 244 | 783119 | 5004 | 49816757 |
Cardiac failure congestive | 104.59 | 11.09 | 820 | 782543 | 83562 | 49738199 |
Hepatitis cholestatic | 102.43 | 11.09 | 265 | 783098 | 5852 | 49815909 |
Liver injury | 100.80 | 11.09 | 694 | 782669 | 24112 | 49797649 |
Red blood cell sedimentation rate abnormal | 98.33 | 11.09 | 66 | 783297 | 16277 | 49805484 |
Therapy cessation | 95.95 | 11.09 | 159 | 783204 | 25852 | 49795909 |
Psoriatic arthropathy | 94.68 | 11.09 | 390 | 782973 | 46642 | 49775119 |
Respiratory depression | 93.95 | 11.09 | 402 | 782961 | 11608 | 49810153 |
Vomiting | 90.54 | 11.09 | 8293 | 775070 | 452465 | 49369296 |
Prothrombin time shortened | 90.24 | 11.09 | 120 | 783243 | 1547 | 49820214 |
Condition aggravated | 88.62 | 11.09 | 3728 | 779635 | 293330 | 49528431 |
Urine abnormality | 88.23 | 11.09 | 254 | 783109 | 5984 | 49815777 |
Blister | 88.11 | 11.09 | 1833 | 781530 | 83585 | 49738176 |
Drug abuse | 87.90 | 11.09 | 1358 | 782005 | 58488 | 49763273 |
Transaminases increased | 84.87 | 11.09 | 728 | 782635 | 27096 | 49794665 |
Accidental exposure to product | 84.07 | 11.09 | 142 | 783221 | 22915 | 49798846 |
Urticaria | 83.86 | 11.09 | 2612 | 780751 | 126949 | 49694812 |
Pyroglutamic acidosis | 83.58 | 11.09 | 63 | 783300 | 380 | 49821381 |
Therapeutic response decreased | 83.46 | 11.09 | 411 | 782952 | 46820 | 49774941 |
Abdominal pain | 83.40 | 11.09 | 4463 | 778900 | 231765 | 49589996 |
Bradypnoea | 81.62 | 11.09 | 160 | 783203 | 2914 | 49818847 |
Therapy interrupted | 80.24 | 11.09 | 117 | 783246 | 20035 | 49801726 |
Contraindicated product administered | 80.14 | 11.09 | 1726 | 781637 | 147232 | 49674529 |
Disease progression | 79.46 | 11.09 | 1026 | 782337 | 94840 | 49726921 |
Acute generalised exanthematous pustulosis | 77.66 | 11.09 | 309 | 783054 | 8629 | 49813132 |
Prothrombin time ratio decreased | 75.92 | 11.09 | 58 | 783305 | 358 | 49821403 |
Miosis | 74.34 | 11.09 | 241 | 783122 | 6069 | 49815692 |
Poisoning | 73.10 | 11.09 | 383 | 782980 | 12046 | 49809715 |
Therapy non-responder | 72.84 | 11.09 | 476 | 782887 | 50546 | 49771215 |
Alanine aminotransferase increased | 72.44 | 11.09 | 1836 | 781527 | 86523 | 49735238 |
Toxic epidermal necrolysis | 70.86 | 11.09 | 562 | 782801 | 20430 | 49801331 |
Glossodynia | 70.29 | 11.09 | 1312 | 782051 | 114257 | 49707504 |
Blood pressure diastolic abnormal | 69.91 | 11.09 | 309 | 783054 | 9052 | 49812709 |
Bone marrow failure | 69.74 | 11.09 | 208 | 783155 | 27416 | 49794345 |
Diarrhoea | 69.60 | 11.09 | 8013 | 775350 | 580463 | 49241298 |
Injection site warmth | 68.49 | 11.09 | 68 | 783295 | 13798 | 49807963 |
No adverse event | 68.48 | 11.09 | 277 | 783086 | 33301 | 49788460 |
Lymphocyte count decreased | 68.39 | 11.09 | 665 | 782698 | 25642 | 49796119 |
Drug intolerance | 68.19 | 11.09 | 2736 | 780627 | 216368 | 49605393 |
Urine leukocyte esterase positive | 68.15 | 11.09 | 143 | 783220 | 2740 | 49819021 |
Mixed liver injury | 67.85 | 11.09 | 159 | 783204 | 3292 | 49818469 |
Hepatic encephalopathy | 67.42 | 11.09 | 312 | 783051 | 9324 | 49812437 |
Intentional self-injury | 65.46 | 11.09 | 595 | 782768 | 22517 | 49799244 |
Ductus arteriosus premature closure | 65.17 | 11.09 | 48 | 783315 | 278 | 49821483 |
Prothrombin time prolonged | 64.70 | 11.09 | 290 | 783073 | 8548 | 49813213 |
Ill-defined disorder | 63.10 | 11.09 | 1193 | 782170 | 53461 | 49768300 |
Surgery | 62.34 | 11.09 | 248 | 783115 | 29957 | 49791804 |
Sleep disorder due to general medical condition, insomnia type | 61.88 | 11.09 | 752 | 782611 | 30695 | 49791066 |
Myocardial infarction | 61.76 | 11.09 | 987 | 782376 | 88040 | 49733721 |
Transplant rejection | 60.28 | 11.09 | 37 | 783326 | 9572 | 49812189 |
Device issue | 59.87 | 11.09 | 138 | 783225 | 19834 | 49801927 |
Unintentional medical device removal | 59.73 | 11.09 | 7 | 783356 | 5428 | 49816333 |
Pruritus | 59.71 | 11.09 | 5131 | 778232 | 278437 | 49543324 |
Haematotoxicity | 59.16 | 11.09 | 24 | 783339 | 7871 | 49813890 |
Oxygen saturation decreased | 58.85 | 11.09 | 1518 | 781845 | 71730 | 49750031 |
Heart rate increased | 58.63 | 11.09 | 1589 | 781774 | 75661 | 49746100 |
Product use in unapproved indication | 57.73 | 11.09 | 1358 | 782005 | 114461 | 49707300 |
White blood cells urine positive | 57.73 | 11.09 | 179 | 783184 | 4399 | 49817362 |
Drug-induced liver injury | 57.54 | 11.09 | 677 | 782686 | 27418 | 49794343 |
Device dislocation | 57.50 | 11.09 | 158 | 783205 | 21388 | 49800373 |
Encephalopathy | 57.42 | 11.09 | 785 | 782578 | 32926 | 49788835 |
Acute kidney injury | 57.20 | 11.09 | 4183 | 779180 | 223875 | 49597886 |
Tachycardia | 56.50 | 11.09 | 1980 | 781383 | 97783 | 49723978 |
Pyrexia | 56.33 | 11.09 | 6715 | 776648 | 373488 | 49448273 |
Product storage error | 54.78 | 11.09 | 65 | 783298 | 12159 | 49809602 |
Acute lung injury | 54.53 | 11.09 | 86 | 783277 | 1307 | 49820454 |
Neoplasm progression | 54.27 | 11.09 | 249 | 783114 | 28908 | 49792853 |
Throat irritation | 53.91 | 11.09 | 710 | 782653 | 29529 | 49792232 |
Crystal urine present | 53.60 | 11.09 | 88 | 783275 | 1386 | 49820375 |
Product prescribing error | 53.52 | 11.09 | 157 | 783206 | 20804 | 49800957 |
Ear pain | 53.35 | 11.09 | 671 | 782692 | 27612 | 49794149 |
Cytomegalovirus infection | 53.13 | 11.09 | 125 | 783238 | 17837 | 49803924 |
Malignant neoplasm progression | 52.85 | 11.09 | 739 | 782624 | 67385 | 49754376 |
Blood pressure systolic abnormal | 52.81 | 11.09 | 248 | 783115 | 7458 | 49814303 |
Blood parathyroid hormone decreased | 52.70 | 11.09 | 22 | 783341 | 7092 | 49814669 |
Device malfunction | 52.52 | 11.09 | 96 | 783267 | 15025 | 49806736 |
Granuloma skin | 51.90 | 11.09 | 13 | 783350 | 5805 | 49815956 |
Abortion spontaneous | 51.71 | 11.09 | 406 | 782957 | 41366 | 49780395 |
Gallbladder injury | 50.81 | 11.09 | 80 | 783283 | 1214 | 49820547 |
Heart rate decreased | 50.12 | 11.09 | 819 | 782544 | 35678 | 49786083 |
Urinary sediment present | 49.71 | 11.09 | 101 | 783262 | 1890 | 49819871 |
Respiratory arrest | 48.76 | 11.09 | 693 | 782670 | 29316 | 49792445 |
Muscle spasticity | 48.47 | 11.09 | 442 | 782921 | 16742 | 49805019 |
Acidosis | 48.19 | 11.09 | 297 | 783066 | 9930 | 49811831 |
Diabetes mellitus | 47.88 | 11.09 | 506 | 782857 | 48527 | 49773234 |
Interstitial lung disease | 47.87 | 11.09 | 559 | 782804 | 52617 | 49769144 |
Rheumatoid nodule | 47.76 | 11.09 | 77 | 783286 | 12658 | 49809103 |
Cholelithiasis | 47.37 | 11.09 | 839 | 782524 | 37134 | 49784627 |
Device difficult to use | 47.11 | 11.09 | 50 | 783313 | 9836 | 49811925 |
Injection site haemorrhage | 46.81 | 11.09 | 171 | 783192 | 21175 | 49800586 |
Infusion site extravasation | 46.71 | 11.09 | 223 | 783140 | 6753 | 49815008 |
Renal papillary necrosis | 46.15 | 11.09 | 34 | 783329 | 197 | 49821564 |
Adverse drug reaction | 45.75 | 11.09 | 591 | 782772 | 54631 | 49767130 |
Arthropathy | 45.67 | 11.09 | 1988 | 781375 | 155918 | 49665843 |
Injury | 45.35 | 11.09 | 1034 | 782329 | 47891 | 49773870 |
Infusion site pain | 45.28 | 11.09 | 337 | 783026 | 12009 | 49809752 |
Orthostatic hypotension | 45.21 | 11.09 | 674 | 782689 | 28807 | 49792954 |
Loss of personal independence in daily activities | 45.17 | 11.09 | 787 | 782576 | 69263 | 49752498 |
Injection site rash | 45.16 | 11.09 | 116 | 783247 | 16061 | 49805700 |
Post transplant lymphoproliferative disorder | 44.78 | 11.09 | 6 | 783357 | 4198 | 49817563 |
Device use error | 44.65 | 11.09 | 13 | 783350 | 5253 | 49816508 |
Oligohydramnios | 44.62 | 11.09 | 192 | 783171 | 5558 | 49816203 |
Cardio-respiratory arrest | 44.20 | 11.09 | 1120 | 782243 | 52772 | 49768989 |
Red blood cells urine positive | 44.20 | 11.09 | 118 | 783245 | 2657 | 49819104 |
Hypotension | 43.64 | 11.09 | 4222 | 779141 | 231247 | 49590514 |
C-reactive protein abnormal | 43.56 | 11.09 | 252 | 783111 | 27557 | 49794204 |
Infusion site swelling | 43.50 | 11.09 | 223 | 783140 | 6953 | 49814808 |
Palmar-plantar erythrodysaesthesia syndrome | 43.41 | 11.09 | 162 | 783201 | 19936 | 49801825 |
Product use issue | 42.99 | 11.09 | 1883 | 781480 | 147592 | 49674169 |
Bone erosion | 42.58 | 11.09 | 72 | 783291 | 11615 | 49810146 |
Adverse event | 42.17 | 11.09 | 453 | 782910 | 43310 | 49778451 |
Injection site mass | 41.83 | 11.09 | 115 | 783248 | 15565 | 49806196 |
Hypertransaminasaemia | 41.72 | 11.09 | 137 | 783226 | 3474 | 49818287 |
Brain oedema | 41.66 | 11.09 | 331 | 783032 | 12039 | 49809722 |
Myelodysplastic syndrome | 41.11 | 11.09 | 110 | 783253 | 15022 | 49806739 |
Metastases to liver | 40.90 | 11.09 | 166 | 783197 | 19938 | 49801823 |
Cardiac failure | 40.88 | 11.09 | 881 | 782482 | 75159 | 49746602 |
Chills | 40.55 | 11.09 | 1858 | 781505 | 94829 | 49726932 |
Rash maculo-papular | 40.44 | 11.09 | 608 | 782755 | 26033 | 49795728 |
Injection site urticaria | 40.30 | 11.09 | 80 | 783283 | 12137 | 49809624 |
Stevens-Johnson syndrome | 40.15 | 11.09 | 514 | 782849 | 21238 | 49800523 |
Myelosuppression | 40.03 | 11.09 | 94 | 783269 | 13423 | 49808338 |
Pathogen resistance | 39.93 | 11.09 | 19 | 783344 | 5670 | 49816091 |
Drug abuser | 39.85 | 11.09 | 115 | 783248 | 2713 | 49819048 |
Liver transplant | 39.51 | 11.09 | 96 | 783267 | 2036 | 49819725 |
Disease recurrence | 38.87 | 11.09 | 169 | 783194 | 19912 | 49801849 |
Emotional distress | 38.54 | 11.09 | 641 | 782722 | 28022 | 49793739 |
Panniculitis | 38.33 | 11.09 | 45 | 783318 | 8458 | 49813303 |
Unevaluable event | 38.16 | 11.09 | 493 | 782870 | 45573 | 49776188 |
Jaundice | 38.13 | 11.09 | 598 | 782765 | 25831 | 49795930 |
Genital haemorrhage | 37.64 | 11.09 | 28 | 783335 | 6546 | 49815215 |
Blood pressure increased | 37.55 | 11.09 | 2466 | 780897 | 130666 | 49691095 |
Analgesic drug level above therapeutic | 37.24 | 11.09 | 27 | 783336 | 152 | 49821609 |
Abdominal pain upper | 37.22 | 11.09 | 2906 | 780457 | 156403 | 49665358 |
Abortion incomplete | 37.05 | 11.09 | 3 | 783360 | 3123 | 49818638 |
Infusion site erythema | 35.95 | 11.09 | 245 | 783118 | 8482 | 49813279 |
Exposure via ingestion | 35.72 | 11.09 | 110 | 783253 | 2693 | 49819068 |
Blood iron abnormal | 34.83 | 11.09 | 5 | 783358 | 3321 | 49818440 |
Blood pressure systolic increased | 34.36 | 11.09 | 754 | 782609 | 34695 | 49787066 |
Blood urine present | 34.14 | 11.09 | 326 | 783037 | 12507 | 49809254 |
Blood alkaline phosphatase increased | 34.13 | 11.09 | 791 | 782572 | 36735 | 49785026 |
Red cell distribution width increased | 33.91 | 11.09 | 238 | 783125 | 8321 | 49813440 |
Transplant dysfunction | 33.88 | 11.09 | 15 | 783348 | 4669 | 49817092 |
Posterior reversible encephalopathy syndrome | 33.79 | 11.09 | 118 | 783245 | 14810 | 49806951 |
Blood pressure diastolic increased | 33.72 | 11.09 | 214 | 783149 | 7229 | 49814532 |
Disturbance in social behaviour | 33.69 | 11.09 | 3 | 783360 | 2891 | 49818870 |
Creatinine renal clearance decreased | 33.20 | 11.09 | 305 | 783058 | 11576 | 49810185 |
Injection site induration | 33.19 | 11.09 | 49 | 783314 | 8348 | 49813413 |
Musculoskeletal disorder | 32.98 | 11.09 | 147 | 783216 | 17202 | 49804559 |
Hypocoagulable state | 32.86 | 11.09 | 55 | 783308 | 881 | 49820880 |
Skin necrosis | 32.64 | 11.09 | 75 | 783288 | 10792 | 49810969 |
Impaired healing | 32.57 | 11.09 | 1356 | 782007 | 68430 | 49753331 |
Drug level increased | 32.53 | 11.09 | 448 | 782915 | 18820 | 49802941 |
Multiple-drug resistance | 32.43 | 11.09 | 6 | 783357 | 3308 | 49818453 |
Cerebrovascular accident | 32.33 | 11.09 | 1169 | 782194 | 93511 | 49728250 |
Metastases to bone | 32.13 | 11.09 | 156 | 783207 | 17839 | 49803922 |
Aspartate aminotransferase increased | 32.08 | 11.09 | 1496 | 781867 | 76502 | 49745259 |
Ear pruritus | 32.07 | 11.09 | 99 | 783264 | 2427 | 49819334 |
Wrong patient received product | 31.99 | 11.09 | 77 | 783286 | 1623 | 49820138 |
Breast cancer | 31.94 | 11.09 | 469 | 782894 | 42421 | 49779340 |
Haemoglobin urine present | 31.89 | 11.09 | 50 | 783313 | 756 | 49821005 |
Mydriasis | 31.85 | 11.09 | 277 | 783086 | 10350 | 49811411 |
Second primary malignancy | 31.81 | 11.09 | 36 | 783327 | 6878 | 49814883 |
Hepatitis toxic | 31.78 | 11.09 | 106 | 783257 | 2710 | 49819051 |
Brain death | 31.63 | 11.09 | 105 | 783258 | 2678 | 49819083 |
Gamma-glutamyltransferase increased | 31.61 | 11.09 | 639 | 782724 | 28984 | 49792777 |
Blood pressure diastolic decreased | 31.59 | 11.09 | 398 | 782965 | 16383 | 49805378 |
Liver function test abnormal | 31.38 | 11.09 | 904 | 782459 | 43435 | 49778326 |
Renal impairment | 31.37 | 11.09 | 911 | 782452 | 74750 | 49747011 |
Hypertensive crisis | 31.12 | 11.09 | 102 | 783261 | 13052 | 49808709 |
Dyspnoea exertional | 31.01 | 11.09 | 582 | 782781 | 50651 | 49771110 |
Full blood count abnormal | 30.99 | 11.09 | 223 | 783140 | 23165 | 49798596 |
Meningitis aseptic | 30.96 | 11.09 | 137 | 783226 | 4015 | 49817746 |
Hypothermia | 30.86 | 11.09 | 303 | 783060 | 11713 | 49810048 |
Sedation complication | 30.86 | 11.09 | 237 | 783126 | 8529 | 49813232 |
Femur fracture | 30.64 | 11.09 | 402 | 782961 | 37062 | 49784699 |
Biliary dyskinesia | 30.59 | 11.09 | 98 | 783265 | 2452 | 49819309 |
Cerebral haematoma | 30.34 | 11.09 | 114 | 783249 | 3097 | 49818664 |
Unresponsive to stimuli | 30.29 | 11.09 | 653 | 782710 | 29956 | 49791805 |
Respiratory rate increased | 30.18 | 11.09 | 289 | 783074 | 11096 | 49810665 |
Urine ketone body present | 30.15 | 11.09 | 92 | 783271 | 2241 | 49819520 |
Lupus-like syndrome | 29.74 | 11.09 | 64 | 783299 | 9427 | 49812334 |
Temperature regulation disorder | 29.67 | 11.09 | 137 | 783226 | 4090 | 49817671 |
Gastrointestinal disorder | 29.64 | 11.09 | 1766 | 781597 | 92690 | 49729071 |
Visceral congestion | 29.62 | 11.09 | 30 | 783333 | 282 | 49821479 |
Congenital pulmonary hypertension | 29.50 | 11.09 | 16 | 783347 | 48 | 49821713 |
Gallbladder disorder | 29.39 | 11.09 | 392 | 782971 | 16350 | 49805411 |
Metastases to lung | 29.26 | 11.09 | 81 | 783282 | 10939 | 49810822 |
Substance abuse | 29.20 | 11.09 | 134 | 783229 | 3990 | 49817771 |
Knee arthroplasty | 29.18 | 11.09 | 385 | 782978 | 35461 | 49786300 |
Neuropathy peripheral | 29.03 | 11.09 | 1213 | 782150 | 95544 | 49726217 |
Haemophagocytic lymphohistiocytosis | 28.93 | 11.09 | 56 | 783307 | 8577 | 49813184 |
Lymphocyte percentage decreased | 28.62 | 11.09 | 101 | 783262 | 2659 | 49819102 |
Anion gap abnormal | 28.56 | 11.09 | 31 | 783332 | 318 | 49821443 |
Feeling abnormal | 28.29 | 11.09 | 1621 | 781742 | 123871 | 49697890 |
Nasopharyngitis | 28.29 | 11.09 | 3406 | 779957 | 189521 | 49632240 |
Night sweats | 28.19 | 11.09 | 700 | 782663 | 32874 | 49788887 |
Acute graft versus host disease | 28.12 | 11.09 | 13 | 783350 | 3945 | 49817816 |
Toxic skin eruption | 28.07 | 11.09 | 282 | 783081 | 10969 | 49810792 |
Complication associated with device | 27.96 | 11.09 | 124 | 783239 | 14531 | 49807230 |
Product quality issue | 27.53 | 11.09 | 325 | 783038 | 30533 | 49791228 |
Respiratory disorder | 27.32 | 11.09 | 654 | 782709 | 30533 | 49791228 |
Blood bilirubin increased | 27.21 | 11.09 | 669 | 782694 | 31369 | 49790392 |
Underdose | 27.04 | 11.09 | 193 | 783170 | 20085 | 49801676 |
Product administration error | 27.02 | 11.09 | 442 | 782921 | 19257 | 49802504 |
Coagulation factor V level decreased | 26.95 | 11.09 | 28 | 783335 | 272 | 49821489 |
Musculoskeletal stiffness | 26.94 | 11.09 | 1671 | 781692 | 126810 | 49694951 |
White blood cell count decreased | 26.81 | 11.09 | 1505 | 781858 | 115217 | 49706544 |
Chest discomfort | 26.76 | 11.09 | 1721 | 781642 | 91001 | 49730760 |
Red blood cell sedimentation rate | 26.71 | 11.09 | 11 | 783352 | 3575 | 49818186 |
Infusion site pruritus | 26.46 | 11.09 | 126 | 783237 | 3811 | 49817950 |
Cell death | 26.46 | 11.09 | 85 | 783278 | 2130 | 49819631 |
Osteonecrosis | 26.42 | 11.09 | 222 | 783141 | 22295 | 49799466 |
Chronic graft versus host disease | 26.38 | 11.09 | 6 | 783357 | 2861 | 49818900 |
Complication of device removal | 26.17 | 11.09 | 16 | 783347 | 4148 | 49817613 |
Cardiotoxicity | 25.87 | 11.09 | 43 | 783320 | 6984 | 49814777 |
Jaundice cholestatic | 25.72 | 11.09 | 151 | 783212 | 4960 | 49816801 |
Urine analysis abnormal | 25.55 | 11.09 | 134 | 783229 | 4216 | 49817545 |
Flushing | 25.38 | 11.09 | 1275 | 782088 | 65740 | 49756021 |
Drug ineffective for unapproved indication | 25.34 | 11.09 | 209 | 783154 | 21072 | 49800689 |
Mucosal inflammation | 25.23 | 11.09 | 453 | 782910 | 39689 | 49782072 |
Blood glucose increased | 25.18 | 11.09 | 877 | 782486 | 70447 | 49751314 |
Anion gap increased | 25.16 | 11.09 | 65 | 783298 | 1434 | 49820327 |
Platelet count decreased | 25.14 | 11.09 | 1288 | 782075 | 99438 | 49722323 |
Culture urine positive | 25.08 | 11.09 | 113 | 783250 | 3338 | 49818423 |
Product substitution issue | 25.01 | 11.09 | 122 | 783241 | 13935 | 49807826 |
Hyperthermia | 24.87 | 11.09 | 204 | 783159 | 7492 | 49814269 |
Memory impairment | 24.85 | 11.09 | 990 | 782373 | 78370 | 49743391 |
Hyponatraemia | 24.84 | 11.09 | 1768 | 781595 | 94371 | 49727390 |
Device breakage | 24.74 | 11.09 | 71 | 783292 | 9476 | 49812285 |
Fear of injection | 24.72 | 11.09 | 35 | 783328 | 6068 | 49815693 |
Prothrombin level increased | 24.66 | 11.09 | 24 | 783339 | 214 | 49821547 |
Medication overuse headache | 24.58 | 11.09 | 39 | 783324 | 596 | 49821165 |
Osteonecrosis of jaw | 24.45 | 11.09 | 355 | 783008 | 32171 | 49789590 |
Coagulation factor VII level decreased | 24.36 | 11.09 | 15 | 783348 | 61 | 49821700 |
Electric shock | 24.31 | 11.09 | 51 | 783312 | 977 | 49820784 |
Blood calcium decreased | 24.24 | 11.09 | 453 | 782910 | 20253 | 49801508 |
Complication of device insertion | 24.12 | 11.09 | 35 | 783328 | 6006 | 49815755 |
Foot deformity | 24.10 | 11.09 | 186 | 783177 | 19024 | 49802737 |
Neutropenia | 24.07 | 11.09 | 1967 | 781396 | 145998 | 49675763 |
Brain stem glioma | 24.06 | 11.09 | 19 | 783344 | 124 | 49821637 |
Bradycardia | 24.04 | 11.09 | 1224 | 782139 | 63202 | 49758559 |
Neurotoxicity | 23.94 | 11.09 | 132 | 783231 | 14608 | 49807153 |
Fixed eruption | 23.91 | 11.09 | 45 | 783318 | 794 | 49820967 |
Diabetic ketoacidosis | 23.88 | 11.09 | 170 | 783193 | 17702 | 49804059 |
Body temperature fluctuation | 23.83 | 11.09 | 76 | 783287 | 1897 | 49819864 |
Cytokine release syndrome | 23.80 | 11.09 | 221 | 783142 | 8413 | 49813348 |
Type I hypersensitivity | 23.64 | 11.09 | 86 | 783277 | 2299 | 49819462 |
Basal cell carcinoma | 23.63 | 11.09 | 239 | 783124 | 23117 | 49798644 |
Varicella zoster virus infection | 23.32 | 11.09 | 5 | 783358 | 2484 | 49819277 |
Glycosylated haemoglobin increased | 23.23 | 11.09 | 85 | 783278 | 10521 | 49811240 |
Gait disturbance | 23.21 | 11.09 | 2002 | 781361 | 148003 | 49673758 |
Premature delivery | 23.18 | 11.09 | 244 | 783119 | 23419 | 49798342 |
Anti-neutrophil cytoplasmic antibody positive vasculitis | 23.16 | 11.09 | 4 | 783359 | 2318 | 49819443 |
Product monitoring error | 23.12 | 11.09 | 7 | 783356 | 2757 | 49819004 |
Pulmonary arterial hypertension | 23.09 | 11.09 | 202 | 783161 | 20117 | 49801644 |
Thrombotic microangiopathy | 23.06 | 11.09 | 65 | 783298 | 8726 | 49813035 |
Hyperleukocytosis | 22.99 | 11.09 | 32 | 783331 | 432 | 49821329 |
Drug dose omission by device | 22.28 | 11.09 | 7 | 783356 | 2692 | 49819069 |
Back pain | 22.16 | 11.09 | 3801 | 779562 | 216229 | 49605532 |
Osteoporosis | 22.12 | 11.09 | 527 | 782836 | 44352 | 49777409 |
Infusion site bruising | 22.12 | 11.09 | 82 | 783281 | 2213 | 49819548 |
Upper gastrointestinal haemorrhage | 22.07 | 11.09 | 360 | 783003 | 15675 | 49806086 |
Pneumonia | 22.01 | 11.09 | 5359 | 778004 | 373042 | 49448719 |
Neutrophil percentage increased | 21.89 | 11.09 | 92 | 783271 | 2635 | 49819126 |
Injection site discolouration | 21.88 | 11.09 | 47 | 783316 | 6927 | 49814834 |
Cholestatic liver injury | 21.86 | 11.09 | 75 | 783288 | 1946 | 49819815 |
Anaemia | 21.86 | 11.09 | 3503 | 779860 | 248953 | 49572808 |
Eosinophilia | 21.82 | 11.09 | 408 | 782955 | 18244 | 49803517 |
Duodenal ulcer perforation | 21.68 | 11.09 | 888 | 782475 | 44723 | 49777038 |
Asphyxia | 21.55 | 11.09 | 151 | 783212 | 5276 | 49816485 |
Stomatitis | 21.45 | 11.09 | 1835 | 781528 | 99509 | 49722252 |
Deep vein thrombosis | 21.41 | 11.09 | 1362 | 782001 | 71942 | 49749819 |
Blood lactic acid increased | 21.37 | 11.09 | 154 | 783209 | 5431 | 49816330 |
Forced expiratory volume decreased | 21.19 | 11.09 | 22 | 783341 | 4372 | 49817389 |
Poor venous access | 21.10 | 11.09 | 249 | 783114 | 10091 | 49811670 |
Coma scale abnormal | 20.89 | 11.09 | 136 | 783227 | 4635 | 49817126 |
Caesarean section | 20.78 | 11.09 | 149 | 783214 | 15490 | 49806271 |
Agranulocytosis | 20.56 | 11.09 | 455 | 782908 | 20966 | 49800795 |
Administration site pain | 20.51 | 11.09 | 37 | 783326 | 631 | 49821130 |
Respiratory acidosis | 20.13 | 11.09 | 161 | 783202 | 5867 | 49815894 |
Pain | 20.04 | 11.09 | 8372 | 774991 | 570531 | 49251230 |
Rash erythematous | 20.03 | 11.09 | 693 | 782670 | 34159 | 49787602 |
Foot operation | 20.03 | 11.09 | 34 | 783329 | 5476 | 49816285 |
Hypoprothrombinaemia | 19.92 | 11.09 | 23 | 783340 | 254 | 49821507 |
Biliary sepsis | 19.91 | 11.09 | 42 | 783321 | 808 | 49820953 |
Renal failure neonatal | 19.82 | 11.09 | 19 | 783344 | 166 | 49821595 |
Specific gravity urine decreased | 19.77 | 11.09 | 37 | 783326 | 650 | 49821111 |
Helicobacter infection | 19.73 | 11.09 | 950 | 782413 | 48752 | 49773009 |
Subacute cutaneous lupus erythematosus | 19.66 | 11.09 | 5 | 783358 | 2210 | 49819551 |
Ovarian hyperstimulation syndrome | 19.65 | 11.09 | 13 | 783350 | 3231 | 49818530 |
Incorrect dose administered by device | 19.64 | 11.09 | 15 | 783348 | 3460 | 49818301 |
Lymphoproliferative disorder | 19.60 | 11.09 | 10 | 783353 | 2867 | 49818894 |
Drug screen positive | 19.44 | 11.09 | 104 | 783259 | 3298 | 49818463 |
Arthritis | 19.39 | 11.09 | 1121 | 782242 | 85600 | 49736161 |
Joint stiffness | 19.37 | 11.09 | 341 | 783022 | 29967 | 49791794 |
Fracture | 19.28 | 11.09 | 167 | 783196 | 16666 | 49805095 |
Cognitive disorder | 19.16 | 11.09 | 851 | 782512 | 43272 | 49778489 |
Ductus arteriosus stenosis foetal | 19.15 | 11.09 | 18 | 783345 | 153 | 49821608 |
Nasal necrosis | 19.15 | 11.09 | 14 | 783349 | 80 | 49821681 |
Haemorrhage | 18.88 | 11.09 | 657 | 782706 | 52784 | 49768977 |
Sexual dysfunction | 18.87 | 11.09 | 14 | 783349 | 3278 | 49818483 |
Graft versus host disease in skin | 18.78 | 11.09 | 8 | 783355 | 2548 | 49819213 |
Inadequate analgesia | 18.77 | 11.09 | 84 | 783279 | 2474 | 49819287 |
Pulmonary embolism | 18.71 | 11.09 | 1823 | 781540 | 99881 | 49721880 |
Seizure | 18.71 | 11.09 | 1570 | 781793 | 116304 | 49705457 |
Oedema | 18.56 | 11.09 | 892 | 782471 | 69289 | 49752472 |
Abortion induced | 18.48 | 11.09 | 78 | 783285 | 9266 | 49812495 |
Unintended pregnancy | 18.46 | 11.09 | 30 | 783333 | 4916 | 49816845 |
Cholesterosis | 18.44 | 11.09 | 28 | 783335 | 411 | 49821350 |
Hallucination | 18.36 | 11.09 | 891 | 782472 | 45766 | 49775995 |
Enthesopathy | 18.27 | 11.09 | 54 | 783309 | 7139 | 49814622 |
Intentional product use issue | 18.25 | 11.09 | 1405 | 781958 | 75513 | 49746248 |
Delirium | 18.25 | 11.09 | 744 | 782619 | 37448 | 49784313 |
Bacterial test | 18.23 | 11.09 | 49 | 783314 | 1108 | 49820653 |
Injury associated with device | 18.20 | 11.09 | 13 | 783350 | 3104 | 49818657 |
Cardiomyopathy | 18.13 | 11.09 | 154 | 783209 | 15432 | 49806329 |
Congenital tricuspid valve incompetence | 18.13 | 11.09 | 14 | 783349 | 88 | 49821673 |
Right ventricular failure | 18.06 | 11.09 | 158 | 783205 | 15735 | 49806026 |
Product adhesion issue | 17.98 | 11.09 | 25 | 783338 | 4367 | 49817394 |
Posturing | 17.88 | 11.09 | 29 | 783334 | 452 | 49821309 |
Hand deformity | 17.85 | 11.09 | 1322 | 782041 | 98877 | 49722884 |
Lip oedema | 17.83 | 11.09 | 97 | 783266 | 3096 | 49818665 |
Vitamin K deficiency | 17.80 | 11.09 | 27 | 783336 | 396 | 49821365 |
Neutropenic sepsis | 17.79 | 11.09 | 313 | 783050 | 13834 | 49807927 |
Pulmonary hypertension | 17.71 | 11.09 | 388 | 782975 | 33029 | 49788732 |
Impaired work ability | 17.62 | 11.09 | 131 | 783232 | 13509 | 49808252 |
Truncus coeliacus thrombosis | 17.54 | 11.09 | 7 | 783356 | 7 | 49821754 |
Labelled drug-drug interaction medication error | 17.47 | 11.09 | 93 | 783270 | 10384 | 49811377 |
Device deployment issue | 17.43 | 11.09 | 17 | 783346 | 3479 | 49818282 |
Hip arthroplasty | 17.39 | 11.09 | 349 | 783014 | 30080 | 49791681 |
Infectious thyroiditis | 17.25 | 11.09 | 8 | 783355 | 15 | 49821746 |
Laboratory test abnormal | 17.20 | 11.09 | 254 | 783109 | 22954 | 49798807 |
Administration site swelling | 17.16 | 11.09 | 45 | 783318 | 1002 | 49820759 |
Decreased appetite | 17.15 | 11.09 | 2790 | 780573 | 198133 | 49623628 |
Acute graft versus host disease in skin | 17.09 | 11.09 | 13 | 783350 | 3005 | 49818756 |
Breast cancer female | 17.08 | 11.09 | 52 | 783311 | 6810 | 49814951 |
Systemic infection | 17.01 | 11.09 | 7 | 783356 | 2276 | 49819485 |
Pneumocystis jirovecii pneumonia | 17.01 | 11.09 | 145 | 783218 | 14518 | 49807243 |
Gallbladder cholesterolosis | 16.95 | 11.09 | 36 | 783327 | 696 | 49821065 |
Shoulder arthroplasty | 16.93 | 11.09 | 17 | 783346 | 3431 | 49818330 |
Fatigue | 16.90 | 11.09 | 10355 | 773008 | 697246 | 49124515 |
Drug reaction with eosinophilia and systemic symptoms | 16.79 | 11.09 | 567 | 782796 | 27857 | 49793904 |
Dyspnoea at rest | 16.77 | 11.09 | 19 | 783344 | 3628 | 49818133 |
Epstein-Barr virus infection | 16.73 | 11.09 | 54 | 783309 | 6943 | 49814818 |
Glutathione decreased | 16.72 | 11.09 | 6 | 783357 | 3 | 49821758 |
Coagulation factor V level increased | 16.72 | 11.09 | 6 | 783357 | 3 | 49821758 |
Bursitis | 16.41 | 11.09 | 454 | 782909 | 21681 | 49800080 |
Human herpesvirus 6 infection | 16.39 | 11.09 | 10 | 783353 | 2596 | 49819165 |
JC virus infection | 16.30 | 11.09 | 4 | 783359 | 1811 | 49819950 |
Metastases to lymph nodes | 16.25 | 11.09 | 55 | 783308 | 6969 | 49814792 |
Hepatitis B reactivation | 16.21 | 11.09 | 6 | 783357 | 2081 | 49819680 |
Acute myeloid leukaemia | 16.20 | 11.09 | 152 | 783211 | 14922 | 49806839 |
Hyperglycaemia | 16.19 | 11.09 | 434 | 782929 | 35971 | 49785790 |
Akathisia | 16.08 | 11.09 | 69 | 783294 | 8160 | 49813601 |
Specific gravity urine increased | 16.06 | 11.09 | 18 | 783345 | 192 | 49821569 |
Abnormal clotting factor | 15.93 | 11.09 | 14 | 783349 | 108 | 49821653 |
Drug eruption | 15.93 | 11.09 | 263 | 783100 | 23343 | 49798418 |
Pregnancy with contraceptive device | 15.93 | 11.09 | 24 | 783339 | 4055 | 49817706 |
Vulvar erosion | 15.91 | 11.09 | 16 | 783347 | 149 | 49821612 |
Tenosynovitis | 15.88 | 11.09 | 97 | 783266 | 10468 | 49811293 |
Graft versus host disease | 15.87 | 11.09 | 46 | 783317 | 6120 | 49815641 |
Pregnancy | 15.80 | 11.09 | 343 | 783020 | 29234 | 49792527 |
Ecchymosis | 15.79 | 11.09 | 233 | 783130 | 9936 | 49811825 |
Macular oedema | 15.77 | 11.09 | 20 | 783343 | 3634 | 49818127 |
Heart rate irregular | 15.77 | 11.09 | 402 | 782961 | 18958 | 49802803 |
Device leakage | 15.76 | 11.09 | 43 | 783320 | 5835 | 49815926 |
Neoplasm malignant | 15.74 | 11.09 | 265 | 783098 | 23450 | 49798311 |
Graft versus host disease in gastrointestinal tract | 15.72 | 11.09 | 12 | 783351 | 2769 | 49818992 |
Splenic vein thrombosis | 15.70 | 11.09 | 22 | 783341 | 299 | 49821462 |
Bacterial test positive | 15.70 | 11.09 | 126 | 783237 | 4597 | 49817164 |
Osmolar gap | 15.66 | 11.09 | 13 | 783350 | 92 | 49821669 |
Peptic ulcer haemorrhage | 15.63 | 11.09 | 43 | 783320 | 986 | 49820775 |
Agitation | 15.61 | 11.09 | 992 | 782371 | 52392 | 49769369 |
Biliary colic | 15.58 | 11.09 | 95 | 783268 | 3164 | 49818597 |
Bladder dilatation | 15.46 | 11.09 | 36 | 783327 | 742 | 49821019 |
Amenorrhoea | 15.46 | 11.09 | 73 | 783290 | 8411 | 49813350 |
Galactorrhoea | 15.43 | 11.09 | 21 | 783342 | 3702 | 49818059 |
Blood pH decreased | 15.38 | 11.09 | 77 | 783286 | 2378 | 49819383 |
Diffuse large B-cell lymphoma recurrent | 15.37 | 11.09 | 3 | 783360 | 1592 | 49820169 |
Food allergy | 15.32 | 11.09 | 193 | 783170 | 7944 | 49813817 |
Leukocyturia | 15.27 | 11.09 | 43 | 783320 | 1000 | 49820761 |
Dilatation intrahepatic duct acquired | 15.26 | 11.09 | 32 | 783331 | 613 | 49821148 |
Sensitisation | 15.19 | 11.09 | 3 | 783360 | 1579 | 49820182 |
Treatment noncompliance | 15.15 | 11.09 | 353 | 783010 | 29797 | 49791964 |
Angioedema | 15.14 | 11.09 | 721 | 782642 | 36955 | 49784806 |
Acute haemorrhagic oedema of infancy | 15.14 | 11.09 | 7 | 783356 | 13 | 49821748 |
Infusion site nodule | 15.09 | 11.09 | 45 | 783318 | 1082 | 49820679 |
Coma hepatic | 15.08 | 11.09 | 31 | 783332 | 585 | 49821176 |
Blood creatinine decreased | 15.07 | 11.09 | 130 | 783233 | 4846 | 49816915 |
Self-medication | 15.04 | 11.09 | 73 | 783290 | 2226 | 49819535 |
Prothrombin level decreased | 15.03 | 11.09 | 28 | 783335 | 490 | 49821271 |
Therapy partial responder | 14.98 | 11.09 | 52 | 783311 | 6539 | 49815222 |
Virologic failure | 14.95 | 11.09 | 3 | 783360 | 1561 | 49820200 |
Hypothyroidism | 14.87 | 11.09 | 408 | 782955 | 33717 | 49788044 |
Tardive dyskinesia | 14.87 | 11.09 | 60 | 783303 | 7219 | 49814542 |
Septic shock | 14.86 | 11.09 | 728 | 782635 | 56447 | 49765314 |
Endophthalmitis | 14.75 | 11.09 | 14 | 783349 | 2902 | 49818859 |
Joint dislocation | 14.74 | 11.09 | 121 | 783242 | 12212 | 49809549 |
Infusion site discomfort | 14.66 | 11.09 | 38 | 783325 | 840 | 49820921 |
Disability | 14.52 | 11.09 | 127 | 783236 | 12648 | 49809113 |
Syncope | 14.43 | 11.09 | 1385 | 781978 | 101617 | 49720144 |
Coronary artery disease | 14.39 | 11.09 | 350 | 783013 | 29376 | 49792385 |
Joint destruction | 14.38 | 11.09 | 24 | 783339 | 3892 | 49817869 |
Visual acuity reduced | 14.38 | 11.09 | 222 | 783141 | 19917 | 49801844 |
Cardiac disorder | 14.36 | 11.09 | 532 | 782831 | 42447 | 49779314 |
Hepatic enzyme increased | 14.34 | 11.09 | 2378 | 780985 | 135002 | 49686759 |
Pancreatic fibrosis | 14.34 | 11.09 | 12 | 783351 | 86 | 49821675 |
Sedation | 14.33 | 11.09 | 595 | 782768 | 30015 | 49791746 |
Dizziness | 14.32 | 11.09 | 4976 | 778387 | 341393 | 49480368 |
Oedema peripheral | 14.30 | 11.09 | 2186 | 781177 | 155775 | 49665986 |
Device use issue | 14.23 | 11.09 | 6 | 783357 | 1923 | 49819838 |
Myopathy | 14.21 | 11.09 | 83 | 783280 | 9056 | 49812705 |
Blood copper decreased | 14.14 | 11.09 | 6 | 783357 | 8 | 49821753 |
Hepatectomy | 14.02 | 11.09 | 11 | 783352 | 71 | 49821690 |
Toxic shock syndrome streptococcal | 14.02 | 11.09 | 12 | 783351 | 89 | 49821672 |
Periorbital cellulitis | 13.95 | 11.09 | 29 | 783334 | 552 | 49821209 |
Anaphylactic reaction | 13.94 | 11.09 | 994 | 782369 | 53061 | 49768700 |
Hyperprolactinaemia | 13.93 | 11.09 | 19 | 783344 | 3346 | 49818415 |
Obstructive airways disorder | 13.90 | 11.09 | 165 | 783198 | 15487 | 49806274 |
Sensitivity to weather change | 13.87 | 11.09 | 47 | 783316 | 5954 | 49815807 |
Open globe injury | 13.86 | 11.09 | 9 | 783354 | 41 | 49821720 |
Serotonin syndrome | 13.85 | 11.09 | 490 | 782873 | 24223 | 49797538 |
Leukopenia | 13.84 | 11.09 | 880 | 782483 | 66648 | 49755113 |
Infusion site rash | 13.82 | 11.09 | 49 | 783314 | 1293 | 49820468 |
Gallbladder adenocarcinoma | 13.82 | 11.09 | 12 | 783351 | 91 | 49821670 |
Spleen congestion | 13.79 | 11.09 | 13 | 783350 | 111 | 49821650 |
Incorrect drug administration rate | 13.77 | 11.09 | 78 | 783285 | 2528 | 49819233 |
Autonomic dysreflexia | 13.75 | 11.09 | 21 | 783342 | 310 | 49821451 |
Mediastinal abscess | 13.74 | 11.09 | 6 | 783357 | 9 | 49821752 |
Gestational diabetes | 13.74 | 11.09 | 64 | 783299 | 7401 | 49814360 |
Cytomegalovirus viraemia | 13.74 | 11.09 | 33 | 783330 | 4676 | 49817085 |
Haematoma muscle | 13.73 | 11.09 | 33 | 783330 | 695 | 49821066 |
Retinitis | 13.71 | 11.09 | 6 | 783357 | 1881 | 49819880 |
Blood phosphorus decreased | 13.65 | 11.09 | 103 | 783260 | 3686 | 49818075 |
Hypercalcaemia | 13.60 | 11.09 | 267 | 783096 | 23085 | 49798676 |
Transverse sinus thrombosis | 13.58 | 11.09 | 27 | 783336 | 497 | 49821264 |
Gallbladder hypofunction | 13.55 | 11.09 | 27 | 783336 | 498 | 49821263 |
Aspergillus infection | 13.45 | 11.09 | 57 | 783306 | 6764 | 49814997 |
Creatinine urine decreased | 13.38 | 11.09 | 15 | 783348 | 160 | 49821601 |
Nitrite urine present | 13.36 | 11.09 | 38 | 783325 | 889 | 49820872 |
Brain compression | 13.32 | 11.09 | 21 | 783342 | 319 | 49821442 |
Neck deformity | 13.29 | 11.09 | 7 | 783356 | 1971 | 49819790 |
Cardiac steatosis | 13.28 | 11.09 | 8 | 783355 | 31 | 49821730 |
Hypoglycaemic coma | 13.27 | 11.09 | 10 | 783353 | 2323 | 49819438 |
Red blood cell sedimentation rate increased | 13.26 | 11.09 | 350 | 783013 | 29066 | 49792695 |
Kidney transplant rejection | 13.24 | 11.09 | 26 | 783337 | 3961 | 49817800 |
Suspected suicide | 13.23 | 11.09 | 134 | 783229 | 5223 | 49816538 |
Cholecystitis acute | 13.15 | 11.09 | 168 | 783195 | 6938 | 49814823 |
Bone density decreased | 13.08 | 11.09 | 109 | 783254 | 10966 | 49810795 |
Respiratory failure | 13.06 | 11.09 | 1224 | 782139 | 89957 | 49731804 |
Intervertebral discitis | 13.06 | 11.09 | 78 | 783285 | 2578 | 49819183 |
Intestinal pseudo-obstruction | 12.97 | 11.09 | 33 | 783330 | 721 | 49821040 |
Hepatitis B | 12.96 | 11.09 | 21 | 783342 | 3445 | 49818316 |
Lethargy | 12.92 | 11.09 | 910 | 782453 | 48522 | 49773239 |
Coronary arterial stent insertion | 12.91 | 11.09 | 13 | 783350 | 2621 | 49819140 |
Exposure during pregnancy | 12.91 | 11.09 | 1658 | 781705 | 119357 | 49702404 |
Cytomegalovirus infection reactivation | 12.88 | 11.09 | 13 | 783350 | 2618 | 49819143 |
Adverse reaction | 12.81 | 11.09 | 79 | 783284 | 8507 | 49813254 |
Product tampering | 12.75 | 11.09 | 16 | 783347 | 194 | 49821567 |
Analgesic drug level therapeutic | 12.74 | 11.09 | 4 | 783359 | 0 | 49821761 |
Generalised bullous fixed drug eruption | 12.74 | 11.09 | 4 | 783359 | 0 | 49821761 |
Neurone-specific enolase increased | 12.74 | 11.09 | 4 | 783359 | 0 | 49821761 |
Fibrin D dimer decreased | 12.74 | 11.09 | 4 | 783359 | 0 | 49821761 |
Therapy change | 12.72 | 11.09 | 40 | 783323 | 5185 | 49816576 |
Stent placement | 12.69 | 11.09 | 21 | 783342 | 3417 | 49818344 |
Neonatal respiratory acidosis | 12.65 | 11.09 | 14 | 783349 | 147 | 49821614 |
Dependence | 12.60 | 11.09 | 60 | 783303 | 1815 | 49819946 |
Eosinophil percentage increased | 12.59 | 11.09 | 38 | 783325 | 920 | 49820841 |
Cerebral infarction | 12.58 | 11.09 | 247 | 783116 | 21357 | 49800404 |
Toxicologic test abnormal | 12.57 | 11.09 | 29 | 783334 | 594 | 49821167 |
Eye irritation | 12.56 | 11.09 | 188 | 783175 | 16952 | 49804809 |
Accidental exposure to product by child | 12.50 | 11.09 | 40 | 783323 | 1000 | 49820761 |
Hyperbilirubinaemia | 12.49 | 11.09 | 213 | 783150 | 9357 | 49812404 |
Migraine with aura | 12.48 | 11.09 | 69 | 783294 | 2216 | 49819545 |
Product preparation error | 12.48 | 11.09 | 31 | 783332 | 4341 | 49817420 |
Chronic kidney disease | 12.47 | 11.09 | 496 | 782867 | 39275 | 49782486 |
Thrombosis | 12.43 | 11.09 | 722 | 782641 | 55111 | 49766650 |
Hyperlipidaemia | 12.42 | 11.09 | 193 | 783170 | 17297 | 49804464 |
Sputum culture positive | 12.38 | 11.09 | 49 | 783314 | 1365 | 49820396 |
Fluid retention | 12.37 | 11.09 | 649 | 782714 | 50000 | 49771761 |
Libido disorder | 12.37 | 11.09 | 9 | 783354 | 51 | 49821710 |
Haemolysis | 12.33 | 11.09 | 145 | 783218 | 5871 | 49815890 |
Myocardial fibrosis | 12.31 | 11.09 | 31 | 783332 | 673 | 49821088 |
Bone disorder | 12.30 | 11.09 | 210 | 783153 | 18542 | 49803219 |
General physical health deterioration | 12.24 | 11.09 | 1977 | 781386 | 140457 | 49681304 |
Diffuse axonal injury | 12.24 | 11.09 | 10 | 783353 | 69 | 49821692 |
Vascular purpura | 12.23 | 11.09 | 44 | 783319 | 1170 | 49820591 |
Serum sickness | 12.22 | 11.09 | 74 | 783289 | 2458 | 49819303 |
Immune reconstitution inflammatory syndrome | 12.22 | 11.09 | 44 | 783319 | 5472 | 49816289 |
Pleural fibrosis | 12.20 | 11.09 | 92 | 783271 | 3292 | 49818469 |
Cholangitis acute | 12.14 | 11.09 | 23 | 783340 | 408 | 49821353 |
Depression | 12.13 | 11.09 | 2316 | 781047 | 163107 | 49658654 |
Administration site erythema | 12.03 | 11.09 | 26 | 783337 | 509 | 49821252 |
Breast cancer stage I | 12.02 | 11.09 | 8 | 783355 | 1982 | 49819779 |
Dysphoria | 12.01 | 11.09 | 36 | 783327 | 4738 | 49817023 |
Tonsillar inflammation | 11.93 | 11.09 | 11 | 783352 | 91 | 49821670 |
Needle issue | 11.89 | 11.09 | 65 | 783298 | 7210 | 49814551 |
Sinus tachycardia | 11.87 | 11.09 | 423 | 782940 | 20931 | 49800830 |
Acute lymphocytic leukaemia recurrent | 11.85 | 11.09 | 8 | 783355 | 1967 | 49819794 |
Dose calculation error | 11.75 | 11.09 | 11 | 783352 | 93 | 49821668 |
Impaired quality of life | 11.70 | 11.09 | 51 | 783312 | 6005 | 49815756 |
Red blood cell spherocytes present | 11.64 | 11.09 | 7 | 783356 | 27 | 49821734 |
Cystitis haemorrhagic | 11.57 | 11.09 | 25 | 783338 | 3677 | 49818084 |
Cholelithiasis obstructive | 11.55 | 11.09 | 6 | 783357 | 16 | 49821745 |
Ascites | 11.52 | 11.09 | 446 | 782917 | 35415 | 49786346 |
Palatal oedema | 11.44 | 11.09 | 23 | 783340 | 427 | 49821334 |
Anaphylactoid reaction | 11.39 | 11.09 | 91 | 783272 | 3315 | 49818446 |
Intentional dose omission | 11.37 | 11.09 | 40 | 783323 | 5010 | 49816751 |
Polycystic ovaries | 11.35 | 11.09 | 13 | 783350 | 2471 | 49819290 |
Lupus vasculitis | 11.33 | 11.09 | 24 | 783339 | 463 | 49821298 |
Lung neoplasm malignant | 11.29 | 11.09 | 170 | 783193 | 15314 | 49806447 |
Blood glucose decreased | 11.29 | 11.09 | 206 | 783157 | 18005 | 49803756 |
Congenital central hypoventilation syndrome | 11.27 | 11.09 | 7 | 783356 | 29 | 49821732 |
Tuberculin test positive | 11.27 | 11.09 | 20 | 783343 | 3166 | 49818595 |
Hernial eventration | 11.27 | 11.09 | 5 | 783358 | 8 | 49821753 |
Acute myocardial infarction | 11.26 | 11.09 | 356 | 783007 | 28917 | 49792844 |
Coagulation factor X level decreased | 11.25 | 11.09 | 9 | 783354 | 60 | 49821701 |
BK virus infection | 11.20 | 11.09 | 17 | 783346 | 2864 | 49818897 |
Melaena | 11.20 | 11.09 | 516 | 782847 | 26348 | 49795413 |
Renal disorder | 11.19 | 11.09 | 332 | 783031 | 27173 | 49794588 |
Metastases to central nervous system | 11.18 | 11.09 | 116 | 783247 | 11166 | 49810595 |
Mesenteric artery thrombosis | 11.16 | 11.09 | 13 | 783350 | 145 | 49821616 |
Pulmonary alveolar haemorrhage | 11.15 | 11.09 | 29 | 783334 | 3998 | 49817763 |
Accidental death | 11.14 | 11.09 | 55 | 783308 | 1689 | 49820072 |
Weight decreased | 11.13 | 11.09 | 3153 | 780210 | 218092 | 49603669 |
Full blood count decreased | 11.12 | 11.09 | 262 | 783101 | 22084 | 49799677 |
Blood thyroid stimulating hormone decreased | 11.11 | 11.09 | 106 | 783257 | 4066 | 49817695 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Toxicity to various agents | 962.24 | 11.73 | 4684 | 385795 | 168977 | 29015071 |
Drug ineffective | 608.64 | 11.73 | 2602 | 387877 | 360568 | 28823480 |
Acute hepatic failure | 525.03 | 11.73 | 716 | 389763 | 11236 | 29172812 |
Overdose | 519.12 | 11.73 | 2259 | 388220 | 77560 | 29106488 |
Intentional overdose | 495.94 | 11.73 | 1369 | 389110 | 37159 | 29146889 |
Infusion related reaction | 484.58 | 11.73 | 1476 | 389003 | 42410 | 29141638 |
Completed suicide | 413.04 | 11.73 | 2311 | 388168 | 87935 | 29096113 |
Hepatocellular injury | 384.49 | 11.73 | 860 | 389619 | 20383 | 29163665 |
Analgesic drug level increased | 343.01 | 11.73 | 164 | 390315 | 428 | 29183620 |
Product dose omission issue | 180.38 | 11.73 | 659 | 389820 | 95724 | 29088324 |
Poisoning deliberate | 171.33 | 11.73 | 287 | 390192 | 5444 | 29178604 |
Drug resistance | 164.06 | 11.73 | 41 | 390438 | 21499 | 29162549 |
Intentional product misuse | 161.86 | 11.73 | 893 | 389586 | 33768 | 29150280 |
Exposure to toxic agent | 149.05 | 11.73 | 177 | 390302 | 2398 | 29181650 |
Liver injury | 146.71 | 11.73 | 434 | 390045 | 12256 | 29171792 |
Accidental overdose | 143.76 | 11.73 | 535 | 389944 | 17058 | 29166990 |
Treatment failure | 142.94 | 11.73 | 166 | 390313 | 36773 | 29147275 |
Cholestasis | 129.98 | 11.73 | 634 | 389845 | 22828 | 29161220 |
Blood pressure fluctuation | 129.78 | 11.73 | 564 | 389915 | 19330 | 29164718 |
Toxic epidermal necrolysis | 124.87 | 11.73 | 523 | 389956 | 17630 | 29166418 |
Chills | 124.20 | 11.73 | 1464 | 389015 | 69836 | 29114212 |
Myocardial infarction | 119.72 | 11.73 | 908 | 389571 | 109388 | 29074660 |
Suicide attempt | 115.40 | 11.73 | 809 | 389670 | 33301 | 29150747 |
Hepatitis | 110.43 | 11.73 | 555 | 389924 | 20228 | 29163820 |
Urticaria | 104.95 | 11.73 | 1144 | 389335 | 53516 | 29130532 |
Hepatitis acute | 101.98 | 11.73 | 248 | 390231 | 6214 | 29177834 |
Therapeutic product effect incomplete | 97.09 | 11.73 | 236 | 390243 | 39069 | 29144979 |
Cardiac failure congestive | 96.64 | 11.73 | 603 | 389876 | 75978 | 29108070 |
Vomiting | 94.72 | 11.73 | 3559 | 386920 | 208701 | 28975347 |
Metabolic acidosis | 90.58 | 11.73 | 826 | 389653 | 36836 | 29147212 |
Hepatic cytolysis | 86.70 | 11.73 | 275 | 390204 | 8072 | 29175976 |
Off label use | 85.75 | 11.73 | 3179 | 387300 | 297621 | 28886427 |
Hospitalisation | 84.27 | 11.73 | 317 | 390162 | 45671 | 29138377 |
Coagulopathy | 79.36 | 11.73 | 455 | 390024 | 17452 | 29166596 |
Drug interaction | 77.96 | 11.73 | 1997 | 388482 | 195388 | 28988660 |
Somnolence | 76.15 | 11.73 | 1699 | 388780 | 92256 | 29091792 |
Injection site pain | 74.60 | 11.73 | 202 | 390277 | 32244 | 29151804 |
Hepatotoxicity | 73.38 | 11.73 | 445 | 390034 | 17422 | 29166626 |
Cardiac failure | 71.07 | 11.73 | 686 | 389793 | 78601 | 29105447 |
Hepatic necrosis | 69.28 | 11.73 | 148 | 390331 | 3394 | 29180654 |
Product use in unapproved indication | 68.36 | 11.73 | 775 | 389704 | 86100 | 29097948 |
Wrong technique in product usage process | 67.59 | 11.73 | 202 | 390277 | 31226 | 29152822 |
Diarrhoea | 67.00 | 11.73 | 3652 | 386827 | 329046 | 28855002 |
Anaphylactic reaction | 66.43 | 11.73 | 605 | 389874 | 26968 | 29157080 |
Death | 66.14 | 11.73 | 3770 | 386709 | 338314 | 28845734 |
Coma | 65.12 | 11.73 | 802 | 389677 | 38648 | 29145400 |
Prothrombin time shortened | 64.81 | 11.73 | 86 | 390393 | 1312 | 29182736 |
Hepatitis cholestatic | 63.46 | 11.73 | 218 | 390261 | 6675 | 29177373 |
Fixed eruption | 62.07 | 11.73 | 78 | 390401 | 1124 | 29182924 |
Contraindicated product administered | 60.54 | 11.73 | 92 | 390387 | 18174 | 29165874 |
Transaminases increased | 60.17 | 11.73 | 508 | 389971 | 22154 | 29161894 |
Anion gap | 58.95 | 11.73 | 60 | 390419 | 676 | 29183372 |
Heart rate decreased | 57.68 | 11.73 | 542 | 389937 | 24370 | 29159678 |
Oxygen saturation decreased | 57.58 | 11.73 | 873 | 389606 | 44064 | 29139984 |
Mixed liver injury | 56.42 | 11.73 | 99 | 390380 | 1952 | 29182096 |
Haematotoxicity | 54.53 | 11.73 | 11 | 390468 | 6688 | 29177360 |
Abdominal pain | 54.24 | 11.73 | 2244 | 388235 | 133113 | 29050935 |
Immune reconstitution inflammatory syndrome | 53.62 | 11.73 | 18 | 390461 | 7784 | 29176264 |
Diabetes mellitus | 52.11 | 11.73 | 310 | 390169 | 39521 | 29144527 |
Ductus arteriosus premature closure | 51.30 | 11.73 | 34 | 390445 | 195 | 29183853 |
Pyroglutamic acidosis | 49.75 | 11.73 | 36 | 390443 | 243 | 29183805 |
Blood pressure diastolic abnormal | 49.22 | 11.73 | 106 | 390373 | 2445 | 29181603 |
Hepatic failure | 48.75 | 11.73 | 633 | 389846 | 30879 | 29153169 |
Cytomegalovirus infection | 48.64 | 11.73 | 151 | 390328 | 23064 | 29160984 |
Therapy non-responder | 47.42 | 11.73 | 228 | 390251 | 30683 | 29153365 |
Myelosuppression | 46.16 | 11.73 | 56 | 390423 | 12171 | 29171877 |
Hepatitis fulminant | 46.00 | 11.73 | 127 | 390352 | 3444 | 29180604 |
Pathogen resistance | 45.78 | 11.73 | 25 | 390454 | 8091 | 29175957 |
Renal impairment | 45.56 | 11.73 | 777 | 389702 | 80556 | 29103492 |
Loss of personal independence in daily activities | 45.53 | 11.73 | 177 | 390302 | 25263 | 29158785 |
Stevens-Johnson syndrome | 43.89 | 11.73 | 370 | 390109 | 16127 | 29167921 |
Methaemoglobinaemia | 43.75 | 11.73 | 104 | 390375 | 2567 | 29181481 |
International normalised ratio increased | 42.99 | 11.73 | 824 | 389655 | 43548 | 29140500 |
Cerebral infarction | 42.69 | 11.73 | 174 | 390305 | 24501 | 29159547 |
Cytokine release syndrome | 42.51 | 11.73 | 308 | 390171 | 12811 | 29171237 |
Progressive multifocal leukoencephalopathy | 40.90 | 11.73 | 33 | 390446 | 8686 | 29175362 |
Confusional state | 40.39 | 11.73 | 2070 | 388409 | 125807 | 29058241 |
Glycosylated haemoglobin increased | 40.21 | 11.73 | 39 | 390440 | 9387 | 29174661 |
Multiple-drug resistance | 39.97 | 11.73 | 3 | 390476 | 3897 | 29180151 |
Graft versus host disease | 39.74 | 11.73 | 41 | 390438 | 9587 | 29174461 |
Disease progression | 39.22 | 11.73 | 804 | 389675 | 81112 | 29102936 |
Liver function test abnormal | 39.07 | 11.73 | 567 | 389912 | 28351 | 29155697 |
Inadequate analgesia | 38.87 | 11.73 | 99 | 390380 | 2555 | 29181493 |
Respiratory depression | 38.51 | 11.73 | 308 | 390171 | 13215 | 29170833 |
Cell death | 38.37 | 11.73 | 84 | 390395 | 1960 | 29182088 |
Pyroglutamate increased | 37.96 | 11.73 | 30 | 390449 | 235 | 29183813 |
Blood glucose increased | 37.55 | 11.73 | 550 | 389929 | 58434 | 29125614 |
Drug-induced liver injury | 36.49 | 11.73 | 442 | 390037 | 21213 | 29162835 |
Blood pressure increased | 36.33 | 11.73 | 1252 | 389227 | 72551 | 29111497 |
Drug abuser | 36.08 | 11.73 | 122 | 390357 | 3705 | 29180343 |
Prothrombin time ratio decreased | 35.78 | 11.73 | 33 | 390446 | 326 | 29183722 |
Therapeutic product effect decreased | 35.53 | 11.73 | 235 | 390244 | 29216 | 29154832 |
Post transplant lymphoproliferative disorder | 35.50 | 11.73 | 14 | 390465 | 5479 | 29178569 |
Jaundice | 34.80 | 11.73 | 562 | 389917 | 28734 | 29155314 |
C-reactive protein abnormal | 34.23 | 11.73 | 22 | 390457 | 6514 | 29177534 |
Blood pressure systolic abnormal | 34.16 | 11.73 | 83 | 390396 | 2078 | 29181970 |
Venoocclusive liver disease | 33.94 | 11.73 | 25 | 390454 | 6892 | 29177156 |
Acute generalised exanthematous pustulosis | 33.92 | 11.73 | 155 | 390324 | 5428 | 29178620 |
Psoriasis | 33.18 | 11.73 | 269 | 390210 | 31958 | 29152090 |
Drug ineffective for unapproved indication | 33.04 | 11.73 | 88 | 390391 | 14126 | 29169922 |
Apparent death | 32.47 | 11.73 | 4 | 390475 | 3500 | 29180548 |
Depressed level of consciousness | 32.43 | 11.73 | 676 | 389803 | 36266 | 29147782 |
Therapy partial responder | 32.39 | 11.73 | 14 | 390465 | 5185 | 29178863 |
Alanine aminotransferase increased | 31.85 | 11.73 | 1191 | 389288 | 69753 | 29114295 |
Unresponsive to stimuli | 31.73 | 11.73 | 487 | 389992 | 24639 | 29159409 |
Fluid retention | 31.54 | 11.73 | 182 | 390297 | 23378 | 29160670 |
Cerebrovascular accident | 31.38 | 11.73 | 774 | 389705 | 76137 | 29107911 |
Medication error | 30.70 | 11.73 | 421 | 390058 | 20790 | 29163258 |
BK virus infection | 30.42 | 11.73 | 12 | 390467 | 4695 | 29179353 |
Throat tightness | 30.00 | 11.73 | 178 | 390301 | 6913 | 29177135 |
Sinusitis | 29.97 | 11.73 | 628 | 389851 | 33722 | 29150326 |
Tachycardia | 29.77 | 11.73 | 1204 | 389275 | 71206 | 29112842 |
Body temperature increased | 29.72 | 11.73 | 307 | 390172 | 14158 | 29169890 |
Renal papillary necrosis | 29.23 | 11.73 | 21 | 390458 | 140 | 29183908 |
Treatment noncompliance | 28.88 | 11.73 | 194 | 390285 | 24033 | 29160015 |
Chronic graft versus host disease | 28.21 | 11.73 | 9 | 390470 | 4020 | 29180028 |
Infusion site extravasation | 28.01 | 11.73 | 98 | 390381 | 3029 | 29181019 |
Respiratory arrest | 27.91 | 11.73 | 488 | 389991 | 25345 | 29158703 |
Hepatorenal failure | 26.69 | 11.73 | 34 | 390445 | 497 | 29183551 |
Substance abuse | 26.58 | 11.73 | 167 | 390312 | 6620 | 29177428 |
Bone marrow failure | 26.51 | 11.73 | 233 | 390246 | 27216 | 29156832 |
Coronary artery disease | 26.43 | 11.73 | 417 | 390062 | 43773 | 29140275 |
Nasal necrosis | 26.16 | 11.73 | 13 | 390466 | 38 | 29184010 |
Dysmorphism | 26.10 | 11.73 | 4 | 390475 | 2967 | 29181081 |
Prescription form tampering | 26.04 | 11.73 | 31 | 390448 | 421 | 29183627 |
Factor VIII inhibition | 26.02 | 11.73 | 26 | 390453 | 286 | 29183762 |
Pyrexia | 25.98 | 11.73 | 4248 | 386231 | 283374 | 28900674 |
Bladder cancer | 25.64 | 11.73 | 60 | 390419 | 10067 | 29173981 |
Acute graft versus host disease in skin | 25.40 | 11.73 | 15 | 390464 | 4649 | 29179399 |
Flushing | 25.28 | 11.73 | 530 | 389949 | 28462 | 29155586 |
Hypotension | 25.24 | 11.73 | 2933 | 387546 | 191421 | 28992627 |
Cardiac disorder | 24.93 | 11.73 | 344 | 390135 | 36919 | 29147129 |
Psoriatic arthropathy | 24.54 | 11.73 | 105 | 390374 | 14586 | 29169462 |
Neuropathy peripheral | 24.49 | 11.73 | 732 | 389747 | 70295 | 29113753 |
Injection site swelling | 24.48 | 11.73 | 55 | 390424 | 9362 | 29174686 |
Miosis | 24.23 | 11.73 | 185 | 390294 | 7824 | 29176224 |
Labelled drug-drug interaction medication error | 24.14 | 11.73 | 81 | 390398 | 12078 | 29171970 |
Mydriasis | 24 | 11.73 | 150 | 390329 | 5935 | 29178113 |
Acute graft versus host disease | 23.81 | 11.73 | 25 | 390454 | 5799 | 29178249 |
Therapeutic response decreased | 23.76 | 11.73 | 210 | 390269 | 24501 | 29159547 |
Blood alkaline phosphatase increased | 23.70 | 11.73 | 516 | 389963 | 27890 | 29156158 |
Nocardiosis | 23.33 | 11.73 | 7 | 390472 | 3253 | 29180795 |
Cardio-respiratory arrest | 23.31 | 11.73 | 852 | 389627 | 49749 | 29134299 |
Aspartate aminotransferase increased | 23.15 | 11.73 | 987 | 389492 | 58738 | 29125310 |
Constipation | 22.90 | 11.73 | 1777 | 388702 | 112383 | 29071665 |
Platelet count decreased | 22.82 | 11.73 | 1139 | 389340 | 103533 | 29080515 |
Viral mutation identified | 22.67 | 11.73 | 3 | 390476 | 2485 | 29181563 |
Infusion site pruritus | 22.55 | 11.73 | 31 | 390448 | 490 | 29183558 |
Dizziness | 22.40 | 11.73 | 2178 | 388301 | 187506 | 28996542 |
Full blood count abnormal | 22.29 | 11.73 | 112 | 390367 | 14901 | 29169147 |
Aspergillus infection | 22.04 | 11.73 | 69 | 390410 | 10512 | 29173536 |
Bronchopulmonary aspergillosis | 22.01 | 11.73 | 86 | 390393 | 12258 | 29171790 |
Coagulation factor VII level decreased | 22.00 | 11.73 | 16 | 390463 | 109 | 29183939 |
COVID-19 treatment | 21.95 | 11.73 | 22 | 390457 | 243 | 29183805 |
Prothrombin time prolonged | 21.88 | 11.73 | 195 | 390284 | 8637 | 29175411 |
Livedo reticularis | 21.87 | 11.73 | 69 | 390410 | 2019 | 29182029 |
Vascular stent thrombosis | 21.85 | 11.73 | 4 | 390475 | 2606 | 29181442 |
Back pain | 21.83 | 11.73 | 1600 | 388879 | 100684 | 29083364 |
Mucocutaneous disorder | 21.77 | 11.73 | 16 | 390463 | 111 | 29183937 |
Mucosal inflammation | 21.74 | 11.73 | 290 | 390189 | 31305 | 29152743 |
Visual acuity reduced | 21.51 | 11.73 | 112 | 390367 | 14764 | 29169284 |
Blood pressure diastolic increased | 21.41 | 11.73 | 101 | 390378 | 3585 | 29180463 |
Therapy cessation | 21.41 | 11.73 | 108 | 390371 | 14354 | 29169694 |
Product prescribing error | 21.40 | 11.73 | 144 | 390335 | 17832 | 29166216 |
Intracranial pressure increased | 21.36 | 11.73 | 97 | 390382 | 3388 | 29180660 |
Anaemia | 21.33 | 11.73 | 2325 | 388154 | 198626 | 28985422 |
Heart rate increased | 21.32 | 11.73 | 669 | 389810 | 38269 | 29145779 |
Agranulocytosis | 21.18 | 11.73 | 382 | 390097 | 19958 | 29164090 |
Unintentional medical device removal | 21.15 | 11.73 | 3 | 390476 | 2358 | 29181690 |
Angina pectoris | 20.89 | 11.73 | 251 | 390228 | 27599 | 29156449 |
Infusion site swelling | 20.71 | 11.73 | 63 | 390416 | 1807 | 29182241 |
Interstitial lung disease | 20.61 | 11.73 | 592 | 389887 | 57126 | 29126922 |
Drug intolerance | 20.51 | 11.73 | 484 | 389995 | 47895 | 29136153 |
Body temperature decreased | 20.35 | 11.73 | 223 | 390256 | 10441 | 29173607 |
Condition aggravated | 20.30 | 11.73 | 1659 | 388820 | 144636 | 29039412 |
Acidosis | 19.95 | 11.73 | 206 | 390273 | 9499 | 29174549 |
Use of accessory respiratory muscles | 19.94 | 11.73 | 24 | 390455 | 330 | 29183718 |
Graft versus host disease in gastrointestinal tract | 19.94 | 11.73 | 9 | 390470 | 3249 | 29180799 |
Injection site bruising | 19.93 | 11.73 | 44 | 390435 | 7536 | 29176512 |
Infusion site pain | 19.90 | 11.73 | 84 | 390395 | 2841 | 29181207 |
Acute myocardial infarction | 19.87 | 11.73 | 487 | 389992 | 47951 | 29136097 |
Kidney transplant rejection | 19.82 | 11.73 | 39 | 390440 | 6966 | 29177082 |
Lip oedema | 19.68 | 11.73 | 69 | 390410 | 2135 | 29181913 |
Hyperlipasaemia | 19.63 | 11.73 | 28 | 390451 | 459 | 29183589 |
Rash maculo-papular | 19.56 | 11.73 | 439 | 390040 | 23850 | 29160198 |
Psychotic disorder | 19.55 | 11.73 | 173 | 390306 | 20181 | 29163867 |
Renal cortical necrosis | 19.49 | 11.73 | 17 | 390462 | 155 | 29183893 |
Injection site haemorrhage | 19.43 | 11.73 | 52 | 390427 | 8334 | 29175714 |
Therapy interrupted | 19.43 | 11.73 | 52 | 390427 | 8334 | 29175714 |
No adverse event | 19.34 | 11.73 | 143 | 390336 | 17335 | 29166713 |
Accidental exposure to product by child | 19.30 | 11.73 | 50 | 390429 | 1304 | 29182744 |
Transplant rejection | 19.24 | 11.73 | 60 | 390419 | 9152 | 29174896 |
Coronary arterial stent insertion | 19.23 | 11.73 | 14 | 390465 | 3883 | 29180165 |
Hyperhidrosis | 19.18 | 11.73 | 1039 | 389440 | 63501 | 29120547 |
Intraocular pressure increased | 19.09 | 11.73 | 21 | 390458 | 4768 | 29179280 |
Hypertransaminasaemia | 18.94 | 11.73 | 96 | 390383 | 3510 | 29180538 |
Peripheral swelling | 18.85 | 11.73 | 670 | 389809 | 63069 | 29120979 |
Oral pruritus | 18.68 | 11.73 | 20 | 390459 | 240 | 29183808 |
Sphincter of Oddi dysfunction | 18.64 | 11.73 | 15 | 390464 | 121 | 29183927 |
Atrial fibrillation | 18.38 | 11.73 | 1175 | 389304 | 104471 | 29079577 |
Anaphylactic shock | 18.21 | 11.73 | 262 | 390217 | 13074 | 29170974 |
Bezoar | 18.11 | 11.73 | 36 | 390443 | 783 | 29183265 |
Syringe issue | 18.10 | 11.73 | 14 | 390465 | 3764 | 29180284 |
Underdose | 17.93 | 11.73 | 88 | 390391 | 11781 | 29172267 |
Diffuse large B-cell lymphoma recurrent | 17.83 | 11.73 | 6 | 390473 | 2591 | 29181457 |
Blood pressure systolic increased | 17.76 | 11.73 | 317 | 390162 | 16528 | 29167520 |
Low birth weight baby | 17.67 | 11.73 | 38 | 390441 | 6570 | 29177478 |
Brain death | 17.65 | 11.73 | 70 | 390409 | 2300 | 29181748 |
Device leakage | 17.60 | 11.73 | 20 | 390459 | 4475 | 29179573 |
Drug reaction with eosinophilia and systemic symptoms | 17.51 | 11.73 | 489 | 389990 | 27503 | 29156545 |
Viral load increased | 17.46 | 11.73 | 3 | 390476 | 2046 | 29182002 |
Pneumonia | 17.45 | 11.73 | 3851 | 386628 | 316321 | 28867727 |
Cardiac failure chronic | 17.45 | 11.73 | 37 | 390442 | 6430 | 29177618 |
Eyelid ptosis | 17.30 | 11.73 | 26 | 390453 | 5160 | 29178888 |
Prothrombin time abnormal | 17.24 | 11.73 | 28 | 390451 | 517 | 29183531 |
Rhinalgia | 17.04 | 11.73 | 23 | 390456 | 357 | 29183691 |
Glucose-6-phosphate dehydrogenase deficiency | 16.91 | 11.73 | 14 | 390465 | 118 | 29183930 |
Oedematous pancreatitis | 16.91 | 11.73 | 25 | 390454 | 424 | 29183624 |
General physical health deterioration | 16.87 | 11.73 | 1150 | 389329 | 101707 | 29082341 |
Lower respiratory tract infection | 16.87 | 11.73 | 464 | 390015 | 26038 | 29158010 |
Prostatic specific antigen increased | 16.84 | 11.73 | 97 | 390382 | 12467 | 29171581 |
Disease recurrence | 16.76 | 11.73 | 132 | 390347 | 15782 | 29168266 |
Band neutrophil percentage decreased | 16.55 | 11.73 | 7 | 390472 | 12 | 29184036 |
Enthesopathy | 16.54 | 11.73 | 15 | 390464 | 3728 | 29180320 |
Environmental exposure | 16.53 | 11.73 | 19 | 390460 | 248 | 29183800 |
Feeling hot | 16.52 | 11.73 | 292 | 390187 | 15196 | 29168852 |
Failure to suspend medication | 16.48 | 11.73 | 23 | 390456 | 369 | 29183679 |
Poisoning | 16.41 | 11.73 | 203 | 390276 | 9790 | 29174258 |
Posterior reversible encephalopathy syndrome | 16.35 | 11.73 | 62 | 390417 | 8914 | 29175134 |
Erythema | 16.35 | 11.73 | 1184 | 389295 | 74422 | 29109626 |
Injection site reaction | 16.31 | 11.73 | 84 | 390395 | 11104 | 29172944 |
Hepatitis toxic | 16.26 | 11.73 | 59 | 390420 | 1857 | 29182191 |
Palmar-plantar erythrodysaesthesia syndrome | 16.21 | 11.73 | 121 | 390358 | 14638 | 29169410 |
Infection | 16.17 | 11.73 | 838 | 389641 | 75913 | 29108135 |
Periportal oedema | 16.15 | 11.73 | 10 | 390469 | 50 | 29183998 |
Dependent personality disorder | 16.13 | 11.73 | 12 | 390467 | 85 | 29183963 |
Paradoxical drug reaction | 16.12 | 11.73 | 8 | 390471 | 2733 | 29181315 |
Coronary artery bypass | 16.10 | 11.73 | 23 | 390456 | 4662 | 29179386 |
Accidental exposure to product | 16.09 | 11.73 | 80 | 390399 | 10673 | 29173375 |
Hepatitis B | 16.08 | 11.73 | 30 | 390449 | 5467 | 29178581 |
Angular cheilitis | 16.04 | 11.73 | 15 | 390464 | 151 | 29183897 |
Myopathy | 15.97 | 11.73 | 78 | 390401 | 10455 | 29173593 |
Blood pH decreased | 15.89 | 11.73 | 63 | 390416 | 2070 | 29181978 |
Gamma-glutamyltransferase increased | 15.88 | 11.73 | 464 | 390015 | 26273 | 29157775 |
Cryopyrin associated periodic syndrome | 15.83 | 11.73 | 11 | 390468 | 69 | 29183979 |
Beta haemolytic streptococcal infection | 15.80 | 11.73 | 25 | 390454 | 451 | 29183597 |
Feeling abnormal | 15.71 | 11.73 | 574 | 389905 | 53871 | 29130177 |
Nipple inflammation | 15.70 | 11.73 | 10 | 390469 | 53 | 29183995 |
Cytomegalovirus chorioretinitis | 15.51 | 11.73 | 12 | 390467 | 3226 | 29180822 |
Parkinsonism | 15.48 | 11.73 | 47 | 390432 | 7231 | 29176817 |
Neutropenic sepsis | 15.46 | 11.73 | 229 | 390250 | 11498 | 29172550 |
Kidney fibrosis | 15.39 | 11.73 | 4 | 390475 | 2043 | 29182005 |
Lymph node calcification | 15.36 | 11.73 | 14 | 390465 | 136 | 29183912 |
Haematemesis | 15.35 | 11.73 | 430 | 390049 | 24196 | 29159852 |
Hepatocellular carcinoma | 15.30 | 11.73 | 45 | 390434 | 6993 | 29177055 |
Dyspnoea at rest | 15.28 | 11.73 | 12 | 390467 | 3202 | 29180846 |
Neutrophil percentage increased | 15.25 | 11.73 | 55 | 390424 | 1726 | 29182322 |
Gastric ulcer perforation | 15.22 | 11.73 | 35 | 390444 | 845 | 29183203 |
Rhabdomyolysis | 15.19 | 11.73 | 652 | 389827 | 60156 | 29123892 |
Cerebral atrophy congenital | 15.00 | 11.73 | 10 | 390469 | 58 | 29183990 |
Nipple disorder | 14.94 | 11.73 | 15 | 390464 | 166 | 29183882 |
Immunosuppressant drug level increased | 14.84 | 11.73 | 25 | 390454 | 4740 | 29179308 |
Cytomegalovirus viraemia | 14.78 | 11.73 | 39 | 390440 | 6281 | 29177767 |
Neuroleptic malignant syndrome | 14.75 | 11.73 | 139 | 390340 | 16009 | 29168039 |
Aptyalism | 14.70 | 11.73 | 19 | 390460 | 282 | 29183766 |
Throat irritation | 14.66 | 11.73 | 179 | 390300 | 8606 | 29175442 |
Incision site complication | 14.65 | 11.73 | 19 | 390460 | 283 | 29183765 |
Sleep disorder due to a general medical condition | 14.64 | 11.73 | 12 | 390467 | 3134 | 29180914 |
Antipsychotic drug level below therapeutic | 14.57 | 11.73 | 4 | 390475 | 1970 | 29182078 |
Prostate cancer | 14.56 | 11.73 | 243 | 390236 | 25284 | 29158764 |
Lymphocyte count abnormal | 14.40 | 11.73 | 28 | 390451 | 599 | 29183449 |
Hepatic encephalopathy | 14.35 | 11.73 | 247 | 390232 | 12788 | 29171260 |
Cryptococcosis | 14.32 | 11.73 | 4 | 390475 | 1948 | 29182100 |
Tenosynovitis | 14.19 | 11.73 | 17 | 390462 | 3716 | 29180332 |
Duodenal ulcer perforation | 14.19 | 11.73 | 48 | 390431 | 1458 | 29182590 |
Patent ductus arteriosus | 14.16 | 11.73 | 80 | 390399 | 3051 | 29180997 |
Erythema multiforme | 14.10 | 11.73 | 160 | 390319 | 7557 | 29176491 |
Pneumonia cytomegaloviral | 14.08 | 11.73 | 9 | 390470 | 2673 | 29181375 |
Cardiomyopathy | 14.06 | 11.73 | 126 | 390353 | 14661 | 29169387 |
Haemolytic anaemia | 14.06 | 11.73 | 188 | 390291 | 9231 | 29174817 |
Hypothermia | 14.04 | 11.73 | 185 | 390294 | 9054 | 29174994 |
Lymphoproliferative disorder | 13.94 | 11.73 | 8 | 390471 | 2519 | 29181529 |
Oesophageal obstruction | 13.82 | 11.73 | 22 | 390457 | 399 | 29183649 |
Asthenia | 13.75 | 11.73 | 2568 | 387911 | 212682 | 28971366 |
Acute haemorrhagic oedema of infancy | 13.73 | 11.73 | 8 | 390471 | 35 | 29184013 |
JC virus infection | 13.71 | 11.73 | 4 | 390475 | 1893 | 29182155 |
Cystitis haemorrhagic | 13.66 | 11.73 | 27 | 390452 | 4815 | 29179233 |
Ureteric obstruction | 13.65 | 11.73 | 40 | 390439 | 1123 | 29182925 |
Angioedema | 13.64 | 11.73 | 533 | 389946 | 31382 | 29152666 |
Bacterial parotitis | 13.61 | 11.73 | 6 | 390473 | 12 | 29184036 |
Product storage error | 13.61 | 11.73 | 42 | 390437 | 6428 | 29177620 |
Product quality issue | 13.61 | 11.73 | 139 | 390340 | 15756 | 29168292 |
Dermo-hypodermitis | 13.58 | 11.73 | 17 | 390462 | 244 | 29183804 |
Pemphigus | 13.55 | 11.73 | 40 | 390439 | 1128 | 29182920 |
Salivary gland calculus | 13.53 | 11.73 | 9 | 390470 | 52 | 29183996 |
Joint swelling | 13.49 | 11.73 | 527 | 389952 | 49103 | 29134945 |
Vascular purpura | 13.47 | 11.73 | 45 | 390434 | 1358 | 29182690 |
Chondrocalcinosis | 13.40 | 11.73 | 18 | 390461 | 278 | 29183770 |
Fragile X syndrome | 13.40 | 11.73 | 8 | 390471 | 37 | 29184011 |
Hypertriglyceridaemia | 13.38 | 11.73 | 52 | 390427 | 7423 | 29176625 |
Pneumococcal infection | 13.37 | 11.73 | 20 | 390459 | 343 | 29183705 |
Device issue | 13.37 | 11.73 | 55 | 390424 | 7725 | 29176323 |
Subcorneal pustular dermatosis | 13.36 | 11.73 | 4 | 390475 | 0 | 29184048 |
Coma scale abnormal | 13.36 | 11.73 | 85 | 390394 | 3384 | 29180664 |
Agitation | 13.33 | 11.73 | 816 | 389663 | 50488 | 29133560 |
Thrombotic microangiopathy | 13.33 | 11.73 | 64 | 390415 | 8617 | 29175431 |
Graft versus host disease in skin | 13.27 | 11.73 | 15 | 390464 | 3364 | 29180684 |
Self-medication | 13.23 | 11.73 | 60 | 390419 | 2094 | 29181954 |
Colour blindness acquired | 13.21 | 11.73 | 10 | 390469 | 73 | 29183975 |
Ejection fraction decreased | 13.16 | 11.73 | 141 | 390338 | 15837 | 29168211 |
Oropharyngeal blistering | 13.14 | 11.73 | 14 | 390465 | 167 | 29183881 |
Oesophageal carcinoma | 13.14 | 11.73 | 25 | 390454 | 4522 | 29179526 |
Coagulation factor V level decreased | 13.13 | 11.73 | 16 | 390463 | 223 | 29183825 |
Metastases to liver | 13.12 | 11.73 | 97 | 390382 | 11759 | 29172289 |
Fatigue | 13.11 | 11.73 | 3858 | 386621 | 312963 | 28871085 |
Weight increased | 13.10 | 11.73 | 854 | 389625 | 75813 | 29108235 |
Hemiparesis | 13.10 | 11.73 | 125 | 390354 | 14361 | 29169687 |
Endophthalmitis | 13.08 | 11.73 | 11 | 390468 | 2837 | 29181211 |
Synovitis | 13.08 | 11.73 | 87 | 390392 | 10803 | 29173245 |
Thrombosis | 13.06 | 11.73 | 451 | 390028 | 42594 | 29141454 |
Injection site pruritus | 13.00 | 11.73 | 37 | 390442 | 5812 | 29178236 |
Drug abuse | 12.95 | 11.73 | 1224 | 389255 | 78659 | 29105389 |
Adverse drug reaction | 12.94 | 11.73 | 231 | 390248 | 23789 | 29160259 |
Dose calculation error | 12.92 | 11.73 | 8 | 390471 | 40 | 29184008 |
Hepatic cirrhosis | 12.91 | 11.73 | 125 | 390354 | 14319 | 29169729 |
Gait disturbance | 12.88 | 11.73 | 815 | 389664 | 72534 | 29111514 |
Mast cell activation syndrome | 12.82 | 11.73 | 14 | 390465 | 172 | 29183876 |
Blood triglycerides increased | 12.81 | 11.73 | 108 | 390371 | 12726 | 29171322 |
Aplasia pure red cell | 12.76 | 11.73 | 34 | 390445 | 5457 | 29178591 |
Drug screen positive | 12.76 | 11.73 | 90 | 390389 | 3711 | 29180337 |
Pleural thickening | 12.71 | 11.73 | 18 | 390461 | 293 | 29183755 |
Allergic cough | 12.68 | 11.73 | 7 | 390472 | 27 | 29184021 |
Blood lactic acid | 12.65 | 11.73 | 19 | 390460 | 327 | 29183721 |
Pneumothorax traumatic | 12.64 | 11.73 | 9 | 390470 | 59 | 29183989 |
Blood ethanol increased | 12.61 | 11.73 | 23 | 390456 | 468 | 29183580 |
Face oedema | 12.48 | 11.73 | 198 | 390281 | 10085 | 29173963 |
Jaundice cholestatic | 12.44 | 11.73 | 97 | 390382 | 4129 | 29179919 |
Macrocephaly | 12.40 | 11.73 | 21 | 390458 | 402 | 29183646 |
Negative pressure pulmonary oedema | 12.37 | 11.73 | 15 | 390464 | 208 | 29183840 |
Myelodysplastic syndrome | 12.36 | 11.73 | 163 | 390316 | 17631 | 29166417 |
Electrocardiogram QT prolonged | 12.31 | 11.73 | 373 | 390106 | 35764 | 29148284 |
Ear injury | 12.30 | 11.73 | 7 | 390472 | 29 | 29184019 |
Paranoid personality disorder | 12.30 | 11.73 | 7 | 390472 | 29 | 29184019 |
Surgery | 12.27 | 11.73 | 98 | 390381 | 11681 | 29172367 |
Respiratory rate increased | 12.26 | 11.73 | 172 | 390307 | 8536 | 29175512 |
Skin degenerative disorder | 12.21 | 11.73 | 6 | 390473 | 17 | 29184031 |
Lip swelling | 12.20 | 11.73 | 231 | 390248 | 12179 | 29171869 |
Crystal urine present | 12.18 | 11.73 | 21 | 390458 | 408 | 29183640 |
Anion gap increased | 12.04 | 11.73 | 47 | 390432 | 1533 | 29182515 |
Hyperthermia | 11.99 | 11.73 | 183 | 390296 | 9247 | 29174801 |
Mucormycosis | 11.94 | 11.73 | 32 | 390447 | 5126 | 29178922 |
Specific gravity urine decreased | 11.92 | 11.73 | 10 | 390469 | 86 | 29183962 |
Infusion site rash | 11.92 | 11.73 | 19 | 390460 | 345 | 29183703 |
Psychomotor retardation | 11.91 | 11.73 | 13 | 390466 | 2963 | 29181085 |
Urine sodium decreased | 11.83 | 11.73 | 13 | 390466 | 161 | 29183887 |
Rhinitis allergic | 11.81 | 11.73 | 68 | 390411 | 2612 | 29181436 |
Specific gravity urine increased | 11.80 | 11.73 | 12 | 390467 | 135 | 29183913 |
Therapeutic product effect variable | 11.78 | 11.73 | 5 | 390474 | 1872 | 29182176 |
Obstructive airways disorder | 11.78 | 11.73 | 91 | 390388 | 10925 | 29173123 |
Macrophages increased | 11.77 | 11.73 | 13 | 390466 | 162 | 29183886 |
Leukopenia | 11.76 | 11.73 | 602 | 389877 | 54601 | 29129447 |
Body temperature fluctuation | 11.76 | 11.73 | 44 | 390435 | 1406 | 29182642 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Toxicity to various agents | 3113.64 | 11.46 | 12233 | 957316 | 351280 | 63177903 |
Completed suicide | 1798.09 | 11.46 | 7404 | 962145 | 217010 | 63312173 |
Intentional overdose | 1660.79 | 11.46 | 3969 | 965580 | 85975 | 63443208 |
Acute hepatic failure | 1580.87 | 11.46 | 1957 | 967592 | 24155 | 63505028 |
Overdose | 1350.57 | 11.46 | 5357 | 964192 | 154209 | 63374974 |
Analgesic drug level increased | 1186.11 | 11.46 | 611 | 968938 | 1659 | 63527524 |
Hepatocellular injury | 1015.34 | 11.46 | 2158 | 967391 | 43077 | 63486106 |
Drug ineffective | 917 | 11.46 | 8158 | 961391 | 832089 | 62697094 |
Infusion related reaction | 627.52 | 11.46 | 4429 | 965120 | 160038 | 63369145 |
Poisoning deliberate | 551.27 | 11.46 | 835 | 968714 | 12623 | 63516560 |
Intentional product misuse | 517.89 | 11.46 | 2308 | 967241 | 69987 | 63459196 |
Suicide attempt | 481.87 | 11.46 | 2231 | 967318 | 68776 | 63460407 |
Metabolic acidosis | 433.46 | 11.46 | 2163 | 967386 | 68795 | 63460388 |
Exposure to toxic agent | 422.49 | 11.46 | 492 | 969057 | 5667 | 63523516 |
Product dose omission issue | 404.40 | 11.46 | 1532 | 968017 | 193215 | 63335968 |
Cholestasis | 373.70 | 11.46 | 1500 | 968049 | 43372 | 63485811 |
Injection site pain | 368.95 | 11.46 | 695 | 968854 | 110713 | 63418470 |
Drug resistance | 314.35 | 11.46 | 71 | 969478 | 35031 | 63494152 |
Liver injury | 295.03 | 11.46 | 1056 | 968493 | 28876 | 63500307 |
Hepatotoxicity | 290.03 | 11.46 | 1281 | 968268 | 38681 | 63490502 |
Blood pressure fluctuation | 289.50 | 11.46 | 1542 | 968007 | 50329 | 63478854 |
Off label use | 267.22 | 11.46 | 7358 | 962191 | 625448 | 62903735 |
Accidental overdose | 256.77 | 11.46 | 1093 | 968456 | 32464 | 63496719 |
Hepatitis | 245.53 | 11.46 | 1342 | 968207 | 44240 | 63484943 |
Coagulopathy | 234.50 | 11.46 | 1027 | 968522 | 30893 | 63498290 |
Hepatic failure | 234.35 | 11.46 | 1531 | 968018 | 53863 | 63475320 |
Coma | 227.00 | 11.46 | 2162 | 967387 | 85453 | 63443730 |
Injection site erythema | 222.83 | 11.46 | 455 | 969094 | 70345 | 63458838 |
Somnolence | 220.11 | 11.46 | 4291 | 965258 | 199354 | 63329829 |
Hepatic necrosis | 209.74 | 11.46 | 421 | 969128 | 8052 | 63521131 |
Cardiac failure congestive | 207.61 | 11.46 | 1133 | 968416 | 129447 | 63399736 |
Anion gap | 205.29 | 11.46 | 192 | 969357 | 1675 | 63527508 |
Device expulsion | 199.06 | 11.46 | 38 | 969511 | 21098 | 63508085 |
Wrong technique in product usage process | 190.01 | 11.46 | 435 | 969114 | 64539 | 63464644 |
Hepatitis acute | 188.39 | 11.46 | 534 | 969015 | 12855 | 63516328 |
Therapeutic product effect incomplete | 185.53 | 11.46 | 861 | 968688 | 102621 | 63426562 |
Vomiting | 183.76 | 11.46 | 10081 | 959468 | 541036 | 62988147 |
Myocardial infarction | 177.11 | 11.46 | 1615 | 967934 | 164206 | 63364977 |
Product use in unapproved indication | 170.98 | 11.46 | 1762 | 967787 | 174856 | 63354327 |
Toxic epidermal necrolysis | 167.55 | 11.46 | 1044 | 968505 | 36122 | 63493061 |
Hepatic cytolysis | 163.42 | 11.46 | 524 | 969025 | 13525 | 63515658 |
Treatment failure | 160.18 | 11.46 | 1062 | 968487 | 115754 | 63413429 |
Drug hypersensitivity | 159.89 | 11.46 | 2562 | 966987 | 235253 | 63293930 |
Prothrombin time shortened | 157.28 | 11.46 | 204 | 969345 | 2645 | 63526538 |
Injection site reaction | 157.17 | 11.46 | 288 | 969261 | 46376 | 63482807 |
Urticaria | 149.68 | 11.46 | 3076 | 966473 | 144241 | 63384942 |
Hepatitis cholestatic | 148.40 | 11.46 | 461 | 969088 | 11694 | 63517489 |
Cholecystitis chronic | 147.23 | 11.46 | 387 | 969162 | 8900 | 63520283 |
Injection site swelling | 144.89 | 11.46 | 249 | 969300 | 41104 | 63488079 |
Depressed level of consciousness | 142.45 | 11.46 | 1860 | 967689 | 79576 | 63449607 |
Hospitalisation | 140.63 | 11.46 | 616 | 968933 | 74591 | 63454592 |
International normalised ratio increased | 138.82 | 11.46 | 1809 | 967740 | 77358 | 63451825 |
Pyroglutamate increased | 135.69 | 11.46 | 97 | 969452 | 551 | 63528632 |
Transaminases increased | 133.15 | 11.46 | 1135 | 968414 | 43459 | 63485724 |
Medication error | 132.37 | 11.46 | 1239 | 968310 | 48727 | 63480456 |
Hepatitis fulminant | 132.34 | 11.46 | 292 | 969257 | 5982 | 63523201 |
Pyroglutamic acidosis | 126.84 | 11.46 | 98 | 969451 | 638 | 63528545 |
Injection site pruritus | 125.13 | 11.46 | 236 | 969313 | 37590 | 63491593 |
Abdominal pain | 122.01 | 11.46 | 5803 | 963746 | 306572 | 63222611 |
Confusional state | 120.90 | 11.46 | 4937 | 964612 | 256207 | 63272976 |
Cytomegalovirus infection | 118.79 | 11.46 | 237 | 969312 | 36962 | 63492221 |
Cardiac failure | 117.49 | 11.46 | 1347 | 968202 | 131026 | 63398157 |
Disease progression | 117.22 | 11.46 | 1464 | 968085 | 140216 | 63388967 |
Psoriasis | 114.54 | 11.46 | 621 | 968928 | 71082 | 63458101 |
Diarrhoea | 113.60 | 11.46 | 9339 | 960210 | 713365 | 62815818 |
Respiratory depression | 111.02 | 11.46 | 667 | 968882 | 22776 | 63506407 |
Mixed liver injury | 109.90 | 11.46 | 250 | 969299 | 5231 | 63523952 |
Heart rate decreased | 108.88 | 11.46 | 1287 | 968262 | 53780 | 63475403 |
Haematotoxicity | 107.89 | 11.46 | 30 | 969519 | 12866 | 63516317 |
Blood pressure diastolic abnormal | 107.82 | 11.46 | 409 | 969140 | 11508 | 63517675 |
Therapy non-responder | 106.78 | 11.46 | 568 | 968981 | 65331 | 63463852 |
Injection site bruising | 105.13 | 11.46 | 245 | 969304 | 36128 | 63493055 |
Body temperature increased | 104.13 | 11.46 | 923 | 968626 | 35743 | 63493440 |
Prothrombin time ratio decreased | 101.79 | 11.46 | 88 | 969461 | 685 | 63528498 |
Oxygen saturation decreased | 100.77 | 11.46 | 2213 | 967336 | 104963 | 63424220 |
Bone marrow failure | 100.18 | 11.46 | 376 | 969173 | 47576 | 63481607 |
Urine abnormality | 99.10 | 11.46 | 289 | 969260 | 7073 | 63522110 |
Condition aggravated | 97.34 | 11.46 | 4590 | 964959 | 367836 | 63161347 |
Acute generalised exanthematous pustulosis | 97.00 | 11.46 | 444 | 969105 | 13614 | 63515569 |
Chills | 96.78 | 11.46 | 2726 | 966823 | 134538 | 63394645 |
Drug interaction | 95.13 | 11.46 | 4460 | 965089 | 357623 | 63171560 |
Intentional self-injury | 93.53 | 11.46 | 752 | 968797 | 28292 | 63500891 |
Drug-induced liver injury | 91.34 | 11.46 | 1107 | 968442 | 46536 | 63482647 |
Pathogen resistance | 91.31 | 11.46 | 37 | 969512 | 12506 | 63516677 |
Red blood cell sedimentation rate abnormal | 88.66 | 11.46 | 69 | 969480 | 16237 | 63512946 |
Myelosuppression | 87.65 | 11.46 | 139 | 969410 | 23691 | 63505492 |
Alanine aminotransferase increased | 87.13 | 11.46 | 2721 | 966828 | 136310 | 63392873 |
Therapy cessation | 86.74 | 11.46 | 228 | 969321 | 32261 | 63496922 |
Renal impairment | 84.28 | 11.46 | 1474 | 968075 | 133543 | 63395640 |
Loss of personal independence in daily activities | 83.81 | 11.46 | 691 | 968858 | 71763 | 63457420 |
Product prescribing error | 82.83 | 11.46 | 263 | 969286 | 35006 | 63494177 |
Heart rate increased | 82.70 | 11.46 | 2005 | 967544 | 96670 | 63432513 |
Post transplant lymphoproliferative disorder | 82.12 | 11.46 | 21 | 969528 | 9523 | 63519660 |
Blood pressure increased | 80.65 | 11.46 | 3266 | 966283 | 169286 | 63359897 |
Blood pressure systolic abnormal | 80.08 | 11.46 | 329 | 969220 | 9613 | 63519570 |
Hepatic encephalopathy | 78.82 | 11.46 | 565 | 968984 | 20501 | 63508682 |
Tachycardia | 78.39 | 11.46 | 2867 | 966682 | 146712 | 63382471 |
Diabetes mellitus | 77.33 | 11.46 | 633 | 968916 | 65841 | 63463342 |
Prothrombin time prolonged | 77.19 | 11.46 | 452 | 969097 | 15289 | 63513894 |
Miosis | 77.17 | 11.46 | 399 | 969150 | 12867 | 63516316 |
Lower respiratory tract infection | 76.16 | 11.46 | 1912 | 967637 | 92702 | 63436481 |
Interstitial lung disease | 74.17 | 11.46 | 1028 | 968521 | 96704 | 63432479 |
Drug intolerance | 73.79 | 11.46 | 2206 | 967343 | 185786 | 63343397 |
Transplant rejection | 73.46 | 11.46 | 92 | 969457 | 17309 | 63511874 |
Fixed eruption | 73.34 | 11.46 | 123 | 969426 | 2036 | 63527147 |
C-reactive protein abnormal | 72.94 | 11.46 | 210 | 969339 | 28837 | 63500346 |
Acute graft versus host disease | 72.59 | 11.46 | 23 | 969526 | 9061 | 63520122 |
Multiple-drug resistance | 72.29 | 11.46 | 7 | 969542 | 6495 | 63522688 |
Cardio-respiratory arrest | 72.13 | 11.46 | 1964 | 967585 | 96429 | 63432754 |
Liver function test abnormal | 71.80 | 11.46 | 1274 | 968275 | 58127 | 63471056 |
Therapy interrupted | 70.77 | 11.46 | 120 | 969429 | 19916 | 63509267 |
Poisoning | 70.73 | 11.46 | 567 | 968982 | 21312 | 63507871 |
Unintentional medical device removal | 70.45 | 11.46 | 9 | 969540 | 6725 | 63522458 |
Stevens-Johnson syndrome | 69.26 | 11.46 | 804 | 968745 | 33445 | 63495738 |
Urine leukocyte esterase positive | 69.10 | 11.46 | 156 | 969393 | 3247 | 63525936 |
Therapeutic response decreased | 68.25 | 11.46 | 481 | 969068 | 51707 | 63477476 |
Throat irritation | 67.99 | 11.46 | 772 | 968777 | 31939 | 63497244 |
Renal papillary necrosis | 66.10 | 11.46 | 50 | 969499 | 314 | 63528869 |
Injection site warmth | 65.86 | 11.46 | 63 | 969486 | 13399 | 63515784 |
Drug ineffective for unapproved indication | 65.76 | 11.46 | 243 | 969306 | 30890 | 63498293 |
Graft versus host disease | 64.86 | 11.46 | 67 | 969482 | 13746 | 63515437 |
Device use error | 64.53 | 11.46 | 10 | 969539 | 6461 | 63522722 |
Crystal urine present | 64.33 | 11.46 | 109 | 969440 | 1820 | 63527363 |
Device issue | 64.30 | 11.46 | 154 | 969395 | 22494 | 63506689 |
Bradypnoea | 64.22 | 11.46 | 197 | 969352 | 4962 | 63524221 |
Respiratory arrest | 63.90 | 11.46 | 1136 | 968413 | 51849 | 63477334 |
Immune reconstitution inflammatory syndrome | 63.80 | 11.46 | 56 | 969493 | 12414 | 63516769 |
Acidosis | 62.99 | 11.46 | 471 | 969078 | 17324 | 63511859 |
Drug abuser | 62.51 | 11.46 | 211 | 969338 | 5597 | 63523586 |
White blood cells urine positive | 62.48 | 11.46 | 201 | 969348 | 5197 | 63523986 |
Accidental exposure to product | 60.93 | 11.46 | 198 | 969351 | 26166 | 63503017 |
Pneumonia | 60.77 | 11.46 | 7425 | 962124 | 552151 | 62977032 |
Psoriatic arthropathy | 59.53 | 11.46 | 393 | 969156 | 42888 | 63486295 |
Jaundice | 58.82 | 11.46 | 1041 | 968508 | 47471 | 63481712 |
Hypotension | 57.95 | 11.46 | 6558 | 962991 | 374416 | 63154767 |
Surgery | 57.78 | 11.46 | 223 | 969326 | 27990 | 63501193 |
Cerebral infarction | 56.80 | 11.46 | 372 | 969177 | 40672 | 63488511 |
Product storage error | 56.65 | 11.46 | 70 | 969479 | 13248 | 63515935 |
Urinary sediment present | 55.29 | 11.46 | 111 | 969438 | 2123 | 63527060 |
Anaphylactic reaction | 54.48 | 11.46 | 1385 | 968164 | 67279 | 63461904 |
Cell death | 54.43 | 11.46 | 159 | 969390 | 3895 | 63525288 |
Drug abuse | 54.32 | 11.46 | 2472 | 967077 | 129902 | 63399281 |
Posterior reversible encephalopathy syndrome | 53.96 | 11.46 | 171 | 969378 | 22775 | 63506408 |
Lymphocyte count decreased | 53.94 | 11.46 | 886 | 968663 | 39813 | 63489370 |
Mydriasis | 53.47 | 11.46 | 404 | 969145 | 14908 | 63514275 |
Myelodysplastic syndrome | 53.31 | 11.46 | 223 | 969326 | 27356 | 63501827 |
Mucosal inflammation | 53.12 | 11.46 | 643 | 968906 | 61941 | 63467242 |
Product monitoring error | 53.10 | 11.46 | 9 | 969540 | 5445 | 63523738 |
Granuloma skin | 52.97 | 11.46 | 13 | 969536 | 6061 | 63523122 |
Injection site haemorrhage | 52.93 | 11.46 | 187 | 969362 | 24091 | 63505092 |
Anaemia | 52.79 | 11.46 | 4937 | 964612 | 373743 | 63155440 |
Injection site mass | 52.63 | 11.46 | 113 | 969436 | 17157 | 63512026 |
Neoplasm progression | 51.89 | 11.46 | 381 | 969168 | 40583 | 63488600 |
Flushing | 51.85 | 11.46 | 1549 | 968000 | 77099 | 63452084 |
Chronic graft versus host disease | 51.76 | 11.46 | 15 | 969534 | 6261 | 63522922 |
Blood parathyroid hormone decreased | 51.58 | 11.46 | 23 | 969526 | 7343 | 63521840 |
Blood pressure diastolic increased | 50.96 | 11.46 | 306 | 969243 | 10446 | 63518737 |
Palmar-plantar erythrodysaesthesia syndrome | 50.90 | 11.46 | 241 | 969308 | 28578 | 63500605 |
Acute lung injury | 50.85 | 11.46 | 121 | 969428 | 2610 | 63526573 |
Blood pressure systolic increased | 50.63 | 11.46 | 1034 | 968515 | 48419 | 63480764 |
Blood alkaline phosphatase increased | 50.34 | 11.46 | 1154 | 968395 | 55125 | 63474058 |
Disease recurrence | 50.25 | 11.46 | 273 | 969276 | 31237 | 63497946 |
Rheumatoid nodule | 50.22 | 11.46 | 70 | 969479 | 12581 | 63516602 |
Transplant dysfunction | 50.13 | 11.46 | 19 | 969530 | 6689 | 63522494 |
Labelled drug-drug interaction medication error | 49.40 | 11.46 | 168 | 969381 | 21894 | 63507289 |
Cerebrovascular accident | 49.00 | 11.46 | 1635 | 967914 | 135948 | 63393235 |
Platelet count decreased | 48.82 | 11.46 | 2042 | 967507 | 165669 | 63363514 |
Acute graft versus host disease in skin | 48.65 | 11.46 | 21 | 969528 | 6834 | 63522349 |
Cytokine release syndrome | 48.57 | 11.46 | 503 | 969046 | 20326 | 63508857 |
Aspergillus infection | 48.40 | 11.46 | 109 | 969440 | 16270 | 63512913 |
Bone erosion | 48.22 | 11.46 | 62 | 969487 | 11533 | 63517650 |
Gallbladder injury | 48.11 | 11.46 | 72 | 969477 | 1076 | 63528107 |
Hypertransaminasaemia | 48.05 | 11.46 | 225 | 969324 | 6966 | 63522217 |
Aspartate aminotransferase increased | 47.85 | 11.46 | 2231 | 967318 | 117557 | 63411626 |
Rash maculo-papular | 47.73 | 11.46 | 982 | 968567 | 46044 | 63483139 |
Glycosylated haemoglobin increased | 47.02 | 11.46 | 107 | 969442 | 15912 | 63513271 |
Emotional distress | 46.82 | 11.46 | 782 | 968767 | 35256 | 63493927 |
Substance abuse | 46.33 | 11.46 | 268 | 969281 | 9024 | 63520159 |
Neuropathy peripheral | 45.62 | 11.46 | 1381 | 968168 | 116144 | 63413039 |
Unresponsive to stimuli | 45.59 | 11.46 | 1035 | 968514 | 49358 | 63479825 |
BK virus infection | 44.75 | 11.46 | 28 | 969521 | 7384 | 63521799 |
Blood glucose increased | 44.61 | 11.46 | 1127 | 968422 | 96946 | 63432237 |
Encephalopathy | 44.21 | 11.46 | 1178 | 968371 | 57641 | 63471542 |
Acute myocardial infarction | 44.16 | 11.46 | 759 | 968790 | 68959 | 63460224 |
Septic shock | 43.93 | 11.46 | 1227 | 968322 | 104210 | 63424973 |
Full blood count abnormal | 43.59 | 11.46 | 265 | 969284 | 29492 | 63499691 |
Device malfunction | 43.17 | 11.46 | 129 | 969420 | 17504 | 63511679 |
Coagulation factor VII level decreased | 43.11 | 11.46 | 31 | 969518 | 178 | 63529005 |
Blood pressure diastolic decreased | 43.10 | 11.46 | 519 | 969030 | 21782 | 63507401 |
Muscle injury | 42.98 | 11.46 | 596 | 968953 | 25841 | 63503342 |
Pruritus | 42.48 | 11.46 | 5340 | 964209 | 307060 | 63222123 |
Therapy partial responder | 42.41 | 11.46 | 55 | 969494 | 10193 | 63518990 |
Metastases to liver | 42.40 | 11.46 | 200 | 969349 | 23741 | 63505442 |
Device difficult to use | 42.20 | 11.46 | 51 | 969498 | 9747 | 63519436 |
Treatment noncompliance | 40.31 | 11.46 | 438 | 969111 | 43044 | 63486139 |
Sinusitis | 40.16 | 11.46 | 2626 | 966923 | 143302 | 63385881 |
Gamma-glutamyltransferase increased | 40.12 | 11.46 | 984 | 968565 | 47526 | 63481657 |
General physical health deterioration | 40.06 | 11.46 | 2591 | 966958 | 201834 | 63327349 |
Nocardiosis | 40.05 | 11.46 | 11 | 969538 | 4756 | 63524427 |
Infusion site extravasation | 40.02 | 11.46 | 206 | 969343 | 6631 | 63522552 |
Second primary malignancy | 39.90 | 11.46 | 78 | 969471 | 12259 | 63516924 |
Hepatitis toxic | 39.79 | 11.46 | 151 | 969398 | 4249 | 63524934 |
Bronchopulmonary aspergillosis | 39.63 | 11.46 | 150 | 969399 | 18935 | 63510248 |
Blister | 39.53 | 11.46 | 1540 | 968009 | 79427 | 63449756 |
Coronary arterial stent insertion | 39.51 | 11.46 | 18 | 969531 | 5674 | 63523509 |
Rheumatoid arthritis | 39.38 | 11.46 | 2923 | 966626 | 161371 | 63367812 |
Folliculitis | 39.20 | 11.46 | 653 | 968896 | 29424 | 63499759 |
Lymphocyte percentage decreased | 39.16 | 11.46 | 156 | 969393 | 4493 | 63524690 |
Alopecia | 39.11 | 11.46 | 2063 | 967486 | 163627 | 63365556 |
Vascular stent thrombosis | 39.10 | 11.46 | 3 | 969546 | 3361 | 63525822 |
Injection site induration | 39.00 | 11.46 | 46 | 969503 | 8886 | 63520297 |
Lymphoproliferative disorder | 38.90 | 11.46 | 14 | 969535 | 5089 | 63524094 |
Mucormycosis | 38.74 | 11.46 | 32 | 969517 | 7309 | 63521874 |
Thrombotic microangiopathy | 38.54 | 11.46 | 125 | 969424 | 16530 | 63512653 |
Red cell distribution width increased | 38.17 | 11.46 | 316 | 969233 | 11993 | 63517190 |
Coronary artery disease | 37.93 | 11.46 | 659 | 968890 | 59774 | 63469409 |
Underdose | 37.85 | 11.46 | 230 | 969319 | 25599 | 63503584 |
Respiratory rate increased | 37.81 | 11.46 | 432 | 969117 | 17899 | 63511284 |
Blood calcium decreased | 37.54 | 11.46 | 566 | 968983 | 24988 | 63504195 |
Irritable bowel syndrome | 37.48 | 11.46 | 779 | 968770 | 36590 | 63492593 |
Abdominal pain upper | 37.35 | 11.46 | 3086 | 966463 | 171944 | 63357239 |
Cytomegalovirus viraemia | 37.20 | 11.46 | 66 | 969483 | 10762 | 63518421 |
Neurotoxicity | 37.10 | 11.46 | 250 | 969299 | 27154 | 63502029 |
Brain death | 36.92 | 11.46 | 158 | 969391 | 4703 | 63524480 |
Device dislocation | 36.88 | 11.46 | 178 | 969371 | 21000 | 63508183 |
Kidney transplant rejection | 36.40 | 11.46 | 54 | 969495 | 9457 | 63519726 |
Panniculitis | 36.39 | 11.46 | 48 | 969501 | 8831 | 63520352 |
Lipodystrophy acquired | 36.35 | 11.46 | 8 | 969541 | 4019 | 63525164 |
Dyspnoea exertional | 36.07 | 11.46 | 838 | 968711 | 72892 | 63456291 |
Contraindicated product administered | 35.94 | 11.46 | 1292 | 968257 | 106537 | 63422646 |
Neutrophil percentage increased | 35.73 | 11.46 | 147 | 969402 | 4298 | 63524885 |
Inadequate analgesia | 35.55 | 11.46 | 136 | 969413 | 3842 | 63525341 |
Exposure via ingestion | 35.45 | 11.46 | 157 | 969392 | 4745 | 63524438 |
Ear pruritus | 35.40 | 11.46 | 104 | 969445 | 2556 | 63526627 |
Virologic failure | 35.38 | 11.46 | 5 | 969544 | 3461 | 63525722 |
Strongyloidiasis | 35.23 | 11.46 | 3 | 969546 | 3087 | 63526096 |
No adverse event | 35.05 | 11.46 | 268 | 969281 | 28293 | 63500890 |
Oedema peripheral | 34.93 | 11.46 | 2704 | 966845 | 207613 | 63321570 |
Gait disturbance | 34.93 | 11.46 | 2175 | 967374 | 169980 | 63359203 |
Cardiac disorder | 34.92 | 11.46 | 609 | 968940 | 55207 | 63473976 |
Abortion incomplete | 34.82 | 11.46 | 3 | 969546 | 3058 | 63526125 |
Myopathy | 34.77 | 11.46 | 142 | 969407 | 17538 | 63511645 |
Biliary dyskinesia | 34.74 | 11.46 | 96 | 969453 | 2276 | 63526907 |
Enthesopathy | 34.71 | 11.46 | 57 | 969492 | 9581 | 63519602 |
Nasal necrosis | 34.41 | 11.46 | 23 | 969526 | 115 | 63529068 |
Metastases to lung | 34.33 | 11.46 | 116 | 969433 | 15148 | 63514035 |
Injury | 33.77 | 11.46 | 1091 | 968458 | 54901 | 63474282 |
Coronary artery bypass | 33.71 | 11.46 | 23 | 969526 | 5792 | 63523391 |
Device leakage | 33.55 | 11.46 | 45 | 969504 | 8221 | 63520962 |
Anion gap abnormal | 33.52 | 11.46 | 41 | 969508 | 499 | 63528684 |
Rash erythematous | 33.45 | 11.46 | 963 | 968586 | 47670 | 63481513 |
Injection site urticaria | 33.37 | 11.46 | 74 | 969475 | 11107 | 63518076 |
Jaundice cholestatic | 33.29 | 11.46 | 234 | 969315 | 8436 | 63520747 |
Injection site rash | 33.16 | 11.46 | 123 | 969426 | 15619 | 63513564 |
Body temperature fluctuation | 33.04 | 11.46 | 117 | 969432 | 3181 | 63526002 |
Graft versus host disease in gastrointestinal tract | 32.79 | 11.46 | 22 | 969527 | 5590 | 63523593 |
Venoocclusive liver disease | 32.67 | 11.46 | 63 | 969486 | 9952 | 63519231 |
Hypothermia | 32.42 | 11.46 | 448 | 969101 | 19408 | 63509775 |
Immunosuppressant drug level increased | 32.11 | 11.46 | 37 | 969512 | 7222 | 63521961 |
Meningitis aseptic | 31.72 | 11.46 | 170 | 969379 | 5560 | 63523623 |
Dyspnoea at rest | 31.69 | 11.46 | 29 | 969520 | 6300 | 63522883 |
Prothrombin level increased | 31.67 | 11.46 | 35 | 969514 | 379 | 63528804 |
Incorrect dose administered by device | 31.64 | 11.46 | 11 | 969538 | 4086 | 63525097 |
Cholelithiasis | 31.55 | 11.46 | 902 | 968647 | 44604 | 63484579 |
Lip oedema | 31.53 | 11.46 | 158 | 969391 | 5031 | 63524152 |
Osteonecrosis | 31.39 | 11.46 | 272 | 969277 | 27957 | 63501226 |
Temperature regulation disorder | 31.31 | 11.46 | 136 | 969413 | 4075 | 63525108 |
Dyspnoea | 31.27 | 11.46 | 9996 | 959553 | 708678 | 62820505 |
Blood urine present | 31.26 | 11.46 | 417 | 969132 | 17923 | 63511260 |
Neutropenia | 30.96 | 11.46 | 3141 | 966408 | 236483 | 63292700 |
Brain oedema | 30.91 | 11.46 | 485 | 969064 | 21590 | 63507593 |
Pulmonary hypertension | 30.87 | 11.46 | 459 | 969090 | 42680 | 63486503 |
Urine analysis abnormal | 30.67 | 11.46 | 169 | 969380 | 5587 | 63523596 |
Red blood cells urine positive | 30.57 | 11.46 | 141 | 969408 | 4337 | 63524846 |
Haemoglobin urine present | 30.43 | 11.46 | 50 | 969499 | 813 | 63528370 |
Agranulocytosis | 30.28 | 11.46 | 771 | 968778 | 37458 | 63491725 |
Coagulation factor V level decreased | 30.16 | 11.46 | 41 | 969508 | 558 | 63528625 |
Cardiomyopathy | 30.15 | 11.46 | 240 | 969309 | 25116 | 63504067 |
Epstein-Barr virus infection | 30.11 | 11.46 | 92 | 969457 | 12396 | 63516787 |
Decreased appetite | 29.97 | 11.46 | 3736 | 965813 | 277553 | 63251630 |
Graft versus host disease in skin | 29.87 | 11.46 | 22 | 969527 | 5325 | 63523858 |
Oedema | 29.86 | 11.46 | 1105 | 968444 | 90830 | 63438353 |
Back pain | 29.70 | 11.46 | 4242 | 965307 | 245929 | 63283254 |
Heart rate irregular | 29.67 | 11.46 | 578 | 968971 | 26835 | 63502348 |
Anion gap increased | 29.65 | 11.46 | 107 | 969442 | 2937 | 63526246 |
Product administration error | 29.63 | 11.46 | 582 | 968967 | 27061 | 63502122 |
JC virus infection | 29.61 | 11.46 | 7 | 969542 | 3348 | 63525835 |
Sedation complication | 29.58 | 11.46 | 261 | 969288 | 10093 | 63519090 |
Fluid retention | 29.56 | 11.46 | 676 | 968873 | 58930 | 63470253 |
Liver transplant | 29.55 | 11.46 | 131 | 969418 | 3961 | 63525222 |
Urine ketone body present | 29.50 | 11.46 | 113 | 969436 | 3194 | 63525989 |
Maternal exposure during pregnancy | 29.48 | 11.46 | 1160 | 968389 | 94724 | 63434459 |
Feeling abnormal | 29.39 | 11.46 | 1675 | 967874 | 131927 | 63397256 |
Tenosynovitis | 29.38 | 11.46 | 86 | 969463 | 11747 | 63517436 |
Duodenal ulcer perforation | 29.12 | 11.46 | 704 | 968845 | 33921 | 63495262 |
Drug screen positive | 29.06 | 11.46 | 166 | 969383 | 5563 | 63523620 |
Respiratory failure | 29.04 | 11.46 | 2058 | 967491 | 159125 | 63370058 |
Electric shock | 29.03 | 11.46 | 57 | 969492 | 1072 | 63528111 |
Hepatic enzyme increased | 28.99 | 11.46 | 2299 | 967250 | 127644 | 63401539 |
Agitation | 28.57 | 11.46 | 1613 | 967936 | 86754 | 63442429 |
Bladder cancer | 28.54 | 11.46 | 78 | 969471 | 10896 | 63518287 |
Haematochezia | 28.51 | 11.46 | 769 | 968780 | 65604 | 63463579 |
Specific gravity urine decreased | 28.47 | 11.46 | 46 | 969503 | 737 | 63528446 |
Thrombosis | 28.42 | 11.46 | 826 | 968723 | 69816 | 63459367 |
Methaemoglobinaemia | 28.29 | 11.46 | 135 | 969414 | 4213 | 63524970 |
Ear pain | 28.23 | 11.46 | 533 | 969016 | 24603 | 63504580 |
Coma scale abnormal | 28.22 | 11.46 | 207 | 969342 | 7567 | 63521616 |
Pyrexia | 28.20 | 11.46 | 9092 | 960457 | 549552 | 62979631 |
Hypocoagulable state | 28.14 | 11.46 | 76 | 969473 | 1777 | 63527406 |
Specific gravity urine increased | 27.91 | 11.46 | 34 | 969515 | 412 | 63528771 |
Atrial fibrillation | 27.88 | 11.46 | 2203 | 967346 | 168886 | 63360297 |
Unevaluable event | 27.83 | 11.46 | 563 | 968986 | 49926 | 63479257 |
Cystitis haemorrhagic | 27.78 | 11.46 | 48 | 969501 | 7908 | 63521275 |
Haemorrhage | 27.77 | 11.46 | 945 | 968604 | 78406 | 63450777 |
Infusion site pain | 27.62 | 11.46 | 258 | 969291 | 10139 | 63519044 |
Chest discomfort | 27.52 | 11.46 | 2064 | 967485 | 114042 | 63415141 |
Acute kidney injury | 27.48 | 11.46 | 7369 | 962180 | 441871 | 63087312 |
Accidental exposure to product by child | 27.38 | 11.46 | 91 | 969458 | 2394 | 63526789 |
Brain stem glioma | 27.38 | 11.46 | 21 | 969528 | 135 | 63529048 |
Ascites | 27.25 | 11.46 | 716 | 968833 | 61285 | 63467898 |
Sleep disorder due to general medical condition, insomnia type | 27.12 | 11.46 | 550 | 968999 | 25720 | 63503463 |
Intracranial pressure increased | 27.05 | 11.46 | 189 | 969360 | 6800 | 63522383 |
Analgesic drug level above therapeutic | 27.02 | 11.46 | 33 | 969516 | 401 | 63528782 |
Skin necrosis | 27.00 | 11.46 | 117 | 969432 | 14212 | 63514971 |
Cytomegalovirus infection reactivation | 26.94 | 11.46 | 28 | 969521 | 5728 | 63523455 |
Diffuse large B-cell lymphoma recurrent | 26.92 | 11.46 | 7 | 969542 | 3139 | 63526044 |
Hyperthermia | 26.68 | 11.46 | 354 | 969195 | 15196 | 63513987 |
Memory impairment | 26.47 | 11.46 | 1036 | 968513 | 84646 | 63444537 |
Livedo reticularis | 26.43 | 11.46 | 118 | 969431 | 3579 | 63525604 |
Neuroleptic malignant syndrome | 26.41 | 11.46 | 244 | 969305 | 24752 | 63504431 |
Osteonecrosis of jaw | 26.38 | 11.46 | 430 | 969119 | 39395 | 63489788 |
Endophthalmitis | 26.37 | 11.46 | 25 | 969524 | 5340 | 63523843 |
Diabetic ketoacidosis | 26.33 | 11.46 | 304 | 969245 | 29541 | 63499642 |
Creatinine renal clearance decreased | 25.88 | 11.46 | 331 | 969218 | 14090 | 63515093 |
Feeling hot | 25.81 | 11.46 | 883 | 968666 | 44780 | 63484403 |
Syncope | 25.80 | 11.46 | 2029 | 967520 | 155606 | 63373577 |
Pulmonary arterial hypertension | 25.78 | 11.46 | 250 | 969299 | 25117 | 63504066 |
Metastases to lymph nodes | 25.77 | 11.46 | 58 | 969491 | 8659 | 63520524 |
Blood bilirubin increased | 25.63 | 11.46 | 1084 | 968465 | 56469 | 63472714 |
Muscle spasticity | 25.58 | 11.46 | 372 | 969177 | 16297 | 63512886 |
Pulmonary alveolar haemorrhage | 25.49 | 11.46 | 69 | 969480 | 9669 | 63519514 |
Drug dose omission by device | 25.49 | 11.46 | 10 | 969539 | 3447 | 63525736 |
Sphincter of Oddi dysfunction | 25.42 | 11.46 | 31 | 969518 | 376 | 63528807 |
Basal cell carcinoma | 25.35 | 11.46 | 319 | 969230 | 30519 | 63498664 |
Impaired work ability | 25.30 | 11.46 | 130 | 969419 | 15089 | 63514094 |
Cytopenia | 25.25 | 11.46 | 133 | 969416 | 15338 | 63513845 |
Orthostatic hypotension | 25.23 | 11.46 | 899 | 968650 | 45839 | 63483344 |
Angina pectoris | 25.05 | 11.46 | 502 | 969047 | 44579 | 63484604 |
Hepatitis B | 25.02 | 11.46 | 49 | 969500 | 7696 | 63521487 |
Culture urine positive | 24.95 | 11.46 | 126 | 969423 | 4025 | 63525158 |
Hypertensive crisis | 24.94 | 11.46 | 166 | 969383 | 18082 | 63511101 |
Human herpesvirus 6 infection | 24.92 | 11.46 | 20 | 969529 | 4634 | 63524549 |
Visual acuity reduced | 24.91 | 11.46 | 274 | 969275 | 26867 | 63502316 |
COVID-19 treatment | 24.66 | 11.46 | 32 | 969517 | 415 | 63528768 |
Acute haemorrhagic oedema of infancy | 24.66 | 11.46 | 14 | 969535 | 49 | 63529134 |
Obstructive airways disorder | 24.63 | 11.46 | 226 | 969323 | 22959 | 63506224 |
Wrong patient received product | 24.62 | 11.46 | 117 | 969432 | 3645 | 63525538 |
Gallbladder disorder | 24.55 | 11.46 | 376 | 969173 | 16654 | 63512529 |
Prostatic specific antigen increased | 24.52 | 11.46 | 60 | 969489 | 8700 | 63520483 |
Laboratory test abnormal | 24.52 | 11.46 | 237 | 969312 | 23826 | 63505357 |
Acute myeloid leukaemia | 24.52 | 11.46 | 279 | 969270 | 27184 | 63501999 |
Disturbance in social behaviour | 24.43 | 11.46 | 14 | 969535 | 3873 | 63525310 |
Forced expiratory volume decreased | 24.37 | 11.46 | 41 | 969508 | 6826 | 63522357 |
Self-medication | 24.34 | 11.46 | 125 | 969424 | 4020 | 63525163 |
Adverse event | 24.33 | 11.46 | 432 | 969117 | 39057 | 63490126 |
Malignant neoplasm progression | 24.30 | 11.46 | 1418 | 968131 | 111453 | 63417730 |
Anti-neutrophil cytoplasmic antibody positive vasculitis | 24.25 | 11.46 | 7 | 969542 | 2929 | 63526254 |
Chondrocalcinosis | 24.02 | 11.46 | 41 | 969508 | 689 | 63528494 |
Cardiotoxicity | 23.85 | 11.46 | 77 | 969472 | 10197 | 63518986 |
Hepatitis B reactivation | 23.77 | 11.46 | 23 | 969526 | 4866 | 63524317 |
Subacute cutaneous lupus erythematosus | 23.57 | 11.46 | 8 | 969541 | 3017 | 63526166 |
Sexual dysfunction | 23.56 | 11.46 | 38 | 969511 | 6433 | 63522750 |
Genital haemorrhage | 23.51 | 11.46 | 29 | 969520 | 5493 | 63523690 |
Right ventricular failure | 23.38 | 11.46 | 208 | 969341 | 21263 | 63507920 |
Blood pH decreased | 23.29 | 11.46 | 129 | 969420 | 4273 | 63524910 |
Leukopenia | 23.23 | 11.46 | 1264 | 968285 | 99978 | 63429205 |
Bacterial test | 23.04 | 11.46 | 54 | 969495 | 1153 | 63528030 |
Drug tolerance decreased | 22.85 | 11.46 | 44 | 969505 | 6954 | 63522229 |
Hallucination | 22.83 | 11.46 | 1325 | 968224 | 71463 | 63457720 |
Poor venous access | 22.71 | 11.46 | 286 | 969263 | 12131 | 63517052 |
Abdominal discomfort | 22.57 | 11.46 | 2397 | 967152 | 179925 | 63349258 |
Sopor | 22.49 | 11.46 | 312 | 969237 | 29349 | 63499834 |
Red blood cell sedimentation rate | 22.47 | 11.46 | 14 | 969535 | 3700 | 63525483 |
Progressive multifocal leukoencephalopathy | 22.41 | 11.46 | 171 | 969378 | 18061 | 63511122 |
Hepatocellular carcinoma | 22.40 | 11.46 | 59 | 969490 | 8344 | 63520839 |
Infusion site pruritus | 22.40 | 11.46 | 88 | 969461 | 2518 | 63526665 |
Chronic kidney disease | 22.36 | 11.46 | 681 | 968868 | 57238 | 63471945 |
Neoplasm malignant | 22.36 | 11.46 | 250 | 969299 | 24438 | 63504745 |
Pneumocystis jirovecii pneumonia | 22.29 | 11.46 | 287 | 969262 | 27347 | 63501836 |
Medication overuse headache | 22.21 | 11.46 | 39 | 969510 | 671 | 63528512 |
Product substitution issue | 22.20 | 11.46 | 167 | 969382 | 17694 | 63511489 |
Drug eruption | 22.05 | 11.46 | 396 | 969153 | 35740 | 63493443 |
Neutropenic sepsis | 22 | 11.46 | 481 | 969068 | 22791 | 63506392 |
Pleurothotonus | 21.97 | 11.46 | 4 | 969545 | 2298 | 63526885 |
Drug reaction with eosinophilia and systemic symptoms | 21.90 | 11.46 | 1011 | 968538 | 53206 | 63475977 |
Adverse drug reaction | 21.88 | 11.46 | 518 | 969031 | 44946 | 63484237 |
Hyperhidrosis | 21.83 | 11.46 | 2171 | 967378 | 122749 | 63406434 |
Vascular purpura | 21.72 | 11.46 | 86 | 969463 | 2470 | 63526713 |
Eyelid ptosis | 21.69 | 11.46 | 72 | 969477 | 9453 | 63519730 |
Throat tightness | 21.68 | 11.46 | 478 | 969071 | 22682 | 63506501 |
Dizziness | 21.65 | 11.46 | 5946 | 963603 | 424217 | 63104966 |
Polyomavirus-associated nephropathy | 21.53 | 11.46 | 25 | 969524 | 4863 | 63524320 |
Accidental poisoning | 21.47 | 11.46 | 59 | 969490 | 1394 | 63527789 |
Constipation | 21.42 | 11.46 | 3838 | 965711 | 225499 | 63303684 |
Fear of injection | 21.26 | 11.46 | 35 | 969514 | 5877 | 63523306 |
Prostate cancer | 21.01 | 11.46 | 193 | 969356 | 19602 | 63509581 |
Metastases to bone | 20.94 | 11.46 | 201 | 969348 | 20234 | 63508949 |
Body temperature decreased | 20.86 | 11.46 | 524 | 969025 | 25404 | 63503779 |
Hepatorenal failure | 20.83 | 11.46 | 51 | 969498 | 1121 | 63528062 |
Dose calculation error | 20.73 | 11.46 | 18 | 969531 | 141 | 63529042 |
Complications of transplanted kidney | 20.66 | 11.46 | 31 | 969518 | 5404 | 63523779 |
Acute myeloid leukaemia recurrent | 20.61 | 11.46 | 8 | 969541 | 2776 | 63526407 |
Nipple disorder | 20.56 | 11.46 | 19 | 969530 | 163 | 63529020 |
Varicella zoster virus infection | 20.45 | 11.46 | 17 | 969532 | 3871 | 63525312 |
Fracture | 20.28 | 11.46 | 182 | 969367 | 18573 | 63510610 |
Hyponatraemia | 20.17 | 11.46 | 2536 | 967013 | 145803 | 63383380 |
Infusion site swelling | 20.11 | 11.46 | 146 | 969403 | 5319 | 63523864 |
Monocyte percentage increased | 20.08 | 11.46 | 71 | 969478 | 1929 | 63527254 |
Infusion site erythema | 20.02 | 11.46 | 174 | 969375 | 6699 | 63522484 |
Acute graft versus host disease in intestine | 19.97 | 11.46 | 15 | 969534 | 3594 | 63525589 |
Mycobacterial infection | 19.89 | 11.46 | 10 | 969539 | 2978 | 63526205 |
Cardiac failure acute | 19.76 | 11.46 | 154 | 969395 | 16190 | 63512993 |
Ill-defined disorder | 19.68 | 11.46 | 830 | 968719 | 43222 | 63485961 |
Cytomegalovirus chorioretinitis | 19.68 | 11.46 | 27 | 969522 | 4885 | 63524298 |
Cholestatic liver injury | 19.59 | 11.46 | 108 | 969441 | 3571 | 63525612 |
Oedematous pancreatitis | 19.49 | 11.46 | 42 | 969507 | 846 | 63528337 |
Angioedema | 19.32 | 11.46 | 1125 | 968424 | 60696 | 63468487 |
Injection site discolouration | 19.31 | 11.46 | 47 | 969502 | 6828 | 63522355 |
Serum sickness | 19.31 | 11.46 | 97 | 969452 | 3092 | 63526091 |
Bacterial test positive | 19.30 | 11.46 | 169 | 969380 | 6521 | 63522662 |
Ventricular tachycardia | 19.21 | 11.46 | 381 | 969168 | 33884 | 63495299 |
Lethargy | 19.18 | 11.46 | 1302 | 968247 | 71292 | 63457891 |
Needle issue | 19.17 | 11.46 | 73 | 969476 | 9199 | 63519984 |
White blood cell count decreased | 19.15 | 11.46 | 2078 | 967471 | 155759 | 63373424 |
Type I hypersensitivity | 19.09 | 11.46 | 105 | 969444 | 3469 | 63525714 |
Gallbladder cholesterolosis | 19.02 | 11.46 | 32 | 969517 | 531 | 63528652 |
Product quality issue | 19.00 | 11.46 | 324 | 969225 | 29475 | 63499708 |
Status epilepticus | 18.98 | 11.46 | 221 | 969328 | 21442 | 63507741 |
Cardiac failure chronic | 18.81 | 11.46 | 71 | 969478 | 8970 | 63520213 |
Hyperprolactinaemia | 18.77 | 11.46 | 20 | 969529 | 4045 | 63525138 |
Mucocutaneous disorder | 18.76 | 11.46 | 16 | 969533 | 122 | 63529061 |
Pulmonary fibrosis | 18.68 | 11.46 | 326 | 969223 | 29552 | 63499631 |
Cryptococcosis | 18.68 | 11.46 | 9 | 969540 | 2746 | 63526437 |
Leukocyturia | 18.47 | 11.46 | 58 | 969491 | 1480 | 63527703 |
Renal disorder | 18.42 | 11.46 | 398 | 969151 | 34967 | 63494216 |
Gestational diabetes | 18.38 | 11.46 | 35 | 969514 | 5555 | 63523628 |
Helicobacter infection | 18.33 | 11.46 | 728 | 968821 | 37634 | 63491549 |
Suspected suicide | 18.33 | 11.46 | 205 | 969344 | 8449 | 63520734 |
Lupus-like syndrome | 18.31 | 11.46 | 69 | 969480 | 8722 | 63520461 |
Secondary immunodeficiency | 18.31 | 11.46 | 9 | 969540 | 2715 | 63526468 |
Macular oedema | 18.27 | 11.46 | 28 | 969521 | 4839 | 63524344 |
Oesophageal carcinoma | 18.08 | 11.46 | 27 | 969522 | 4716 | 63524467 |
Food allergy | 18.02 | 11.46 | 189 | 969360 | 7662 | 63521521 |
Haemolysis | 18.00 | 11.46 | 249 | 969300 | 10790 | 63518393 |
Rhabdomyolysis | 17.87 | 11.46 | 1163 | 968386 | 90563 | 63438620 |
Acquired gene mutation | 17.81 | 11.46 | 4 | 969545 | 1982 | 63527201 |
Hyperglycaemia | 17.79 | 11.46 | 742 | 968807 | 60226 | 63468957 |
Hyperbilirubinaemia | 17.79 | 11.46 | 431 | 969118 | 20774 | 63508409 |
Syringe issue | 17.74 | 11.46 | 23 | 969526 | 4263 | 63524920 |
Hepatic cirrhosis | 17.73 | 11.46 | 283 | 969266 | 26015 | 63503168 |
Candida infection | 17.72 | 11.46 | 349 | 969200 | 31070 | 63498113 |
Infusion site discomfort | 17.71 | 11.46 | 37 | 969512 | 729 | 63528454 |
Body height below normal | 17.70 | 11.46 | 3 | 969546 | 1815 | 63527368 |
Osteoporosis | 17.69 | 11.46 | 489 | 969060 | 41591 | 63487592 |
Renal cortical necrosis | 17.67 | 11.46 | 22 | 969527 | 273 | 63528910 |
Intentional product use issue | 17.64 | 11.46 | 1664 | 967885 | 93700 | 63435483 |
Bursitis | 17.52 | 11.46 | 435 | 969114 | 21050 | 63508133 |
Red blood cell sedimentation rate increased | 17.30 | 11.46 | 348 | 969201 | 30887 | 63498296 |
Truncus coeliacus thrombosis | 17.27 | 11.46 | 7 | 969542 | 8 | 63529175 |
Neonatal respiratory acidosis | 17.25 | 11.46 | 11 | 969538 | 50 | 63529133 |
Pneumonia cytomegaloviral | 17.23 | 11.46 | 24 | 969525 | 4315 | 63524868 |
Transplant failure | 17.15 | 11.46 | 19 | 969530 | 3775 | 63525408 |
Abortion spontaneous | 17.15 | 11.46 | 270 | 969279 | 24873 | 63504310 |
Beta haemolytic streptococcal infection | 17.13 | 11.46 | 65 | 969484 | 1829 | 63527354 |
Seizure | 17.09 | 11.46 | 2222 | 967327 | 164670 | 63364513 |
Prothrombin time abnormal | 17.08 | 11.46 | 39 | 969510 | 818 | 63528365 |
Viral load increased | 17.05 | 11.46 | 8 | 969541 | 2479 | 63526704 |
Long QT syndrome | 17.05 | 11.46 | 32 | 969517 | 5107 | 63524076 |
Lip swelling | 17.04 | 11.46 | 613 | 968936 | 31294 | 63497889 |
Galactorrhoea | 17.03 | 11.46 | 14 | 969535 | 3205 | 63525978 |
Faeces discoloured | 17.02 | 11.46 | 507 | 969042 | 25222 | 63503961 |
Systemic candida | 16.97 | 11.46 | 34 | 969515 | 5295 | 63523888 |
Ductus arteriosus stenosis foetal | 16.94 | 11.46 | 12 | 969537 | 67 | 63529116 |
Cognitive disorder | 16.93 | 11.46 | 1001 | 968548 | 54086 | 63475097 |
Gastrointestinal toxicity | 16.91 | 11.46 | 34 | 969515 | 5288 | 63523895 |
Cholesterosis | 16.90 | 11.46 | 24 | 969525 | 341 | 63528842 |
Infection | 16.87 | 11.46 | 2479 | 967070 | 182401 | 63346782 |
Ovarian hyperstimulation syndrome | 16.83 | 11.46 | 11 | 969538 | 2834 | 63526349 |
Toxic skin eruption | 16.80 | 11.46 | 394 | 969155 | 18890 | 63510293 |
Kussmaul respiration | 16.78 | 11.46 | 25 | 969524 | 372 | 63528811 |
Delirium | 16.72 | 11.46 | 1232 | 968317 | 67962 | 63461221 |
Sedation | 16.71 | 11.46 | 773 | 968776 | 40689 | 63488494 |
Aplasia pure red cell | 16.68 | 11.46 | 52 | 969497 | 6962 | 63522221 |
Systemic mycosis | 16.67 | 11.46 | 7 | 969542 | 2316 | 63526867 |
Intervertebral discitis | 16.55 | 11.46 | 107 | 969442 | 3750 | 63525433 |
Disability | 16.50 | 11.46 | 111 | 969438 | 12061 | 63517122 |
Vulvar erosion | 16.39 | 11.46 | 16 | 969533 | 148 | 63529035 |
Red blood cell spherocytes present | 16.39 | 11.46 | 9 | 969540 | 29 | 63529154 |
Glutathione decreased | 16.39 | 11.46 | 9 | 969540 | 29 | 63529154 |
Psychotic disorder | 16.35 | 11.46 | 395 | 969154 | 34183 | 63495000 |
Nitrite urine present | 16.31 | 11.46 | 44 | 969505 | 1028 | 63528155 |
Concomitant disease aggravated | 16.28 | 11.46 | 104 | 969445 | 11438 | 63517745 |
Bezoar | 16.27 | 11.46 | 71 | 969478 | 2132 | 63527051 |
Foot deformity | 16.21 | 11.46 | 164 | 969385 | 16340 | 63512843 |
Retinal haemorrhage | 16.11 | 11.46 | 57 | 969492 | 7341 | 63521842 |
Pleural thickening | 16.10 | 11.46 | 82 | 969467 | 2628 | 63526555 |
Systemic infection | 16.08 | 11.46 | 25 | 969524 | 4296 | 63524887 |
Akathisia | 16.08 | 11.46 | 104 | 969445 | 11406 | 63517777 |
Mycobacterium chelonae infection | 16.06 | 11.46 | 6 | 969543 | 2131 | 63527052 |
Dermo-hypodermitis | 16.01 | 11.46 | 29 | 969520 | 512 | 63528671 |
Factor VIII inhibition | 15.99 | 11.46 | 22 | 969527 | 303 | 63528880 |
Acute graft versus host disease in liver | 15.96 | 11.46 | 3 | 969546 | 1684 | 63527499 |
Fatigue | 15.92 | 11.46 | 10665 | 958884 | 738065 | 62791118 |
Erythema | 15.91 | 11.46 | 3116 | 966433 | 183954 | 63345229 |
Pancytopenia | 15.79 | 11.46 | 1899 | 967650 | 141410 | 63387773 |
Gastric ulcer perforation | 15.78 | 11.46 | 61 | 969488 | 1732 | 63527451 |
Gingival hypertrophy | 15.74 | 11.46 | 11 | 969538 | 2736 | 63526447 |
Stent placement | 15.72 | 11.46 | 38 | 969511 | 5533 | 63523650 |
Use of accessory respiratory muscles | 15.69 | 11.46 | 23 | 969526 | 337 | 63528846 |
Mean cell haemoglobin concentration decreased | 15.68 | 11.46 | 102 | 969447 | 3582 | 63525601 |
Glucose-6-phosphate dehydrogenase deficiency | 15.68 | 11.46 | 22 | 969527 | 309 | 63528874 |
Band neutrophil percentage decreased | 15.68 | 11.46 | 7 | 969542 | 12 | 63529171 |
Sleep disorder due to a general medical condition | 15.65 | 11.46 | 67 | 969482 | 8167 | 63521016 |
Full blood count decreased | 15.57 | 11.46 | 242 | 969307 | 22340 | 63506843 |
Pancreatic fibrosis | 15.56 | 11.46 | 13 | 969536 | 96 | 63529087 |
Respiratory acidosis | 15.54 | 11.46 | 221 | 969328 | 9634 | 63519549 |
Hemiparesis | 15.44 | 11.46 | 336 | 969213 | 29491 | 63499692 |
Retinitis | 15.42 | 11.46 | 6 | 969543 | 2079 | 63527104 |
Blood creatinine decreased | 15.38 | 11.46 | 168 | 969381 | 6882 | 63522301 |
Complication of device removal | 15.30 | 11.46 | 16 | 969533 | 3264 | 63525919 |
Failure of child resistant product closure | 15.19 | 11.46 | 11 | 969538 | 64 | 63529119 |
Peritonitis bacterial | 15.17 | 11.46 | 77 | 969472 | 8966 | 63520217 |
Palatal oedema | 15.17 | 11.46 | 46 | 969503 | 1151 | 63528032 |
Eosinophilia | 15.16 | 11.46 | 709 | 968840 | 37367 | 63491816 |
Mania | 15.11 | 11.46 | 164 | 969385 | 16122 | 63513061 |
Therapy change | 15.09 | 11.46 | 48 | 969501 | 6386 | 63522797 |
Lung neoplasm malignant | 15.07 | 11.46 | 229 | 969320 | 21219 | 63507964 |
Failure to suspend medication | 15.01 | 11.46 | 24 | 969525 | 381 | 63528802 |
Apparent death | 14.96 | 11.46 | 11 | 969538 | 2665 | 63526518 |
Asthenia | 14.96 | 11.46 | 6002 | 963547 | 422042 | 63107141 |
Nipple inflammation | 14.96 | 11.46 | 10 | 969539 | 50 | 63529133 |
Abnormal clotting factor | 14.86 | 11.46 | 13 | 969536 | 103 | 63529080 |
Renal failure neonatal | 14.80 | 11.46 | 11 | 969538 | 67 | 63529116 |
Vitamin K deficiency | 14.77 | 11.46 | 32 | 969517 | 647 | 63528536 |
Gallbladder adenocarcinoma | 14.76 | 11.46 | 13 | 969536 | 104 | 63529079 |
Infection reactivation | 14.76 | 11.46 | 6 | 969543 | 2024 | 63527159 |
Post-traumatic stress disorder | 14.71 | 11.46 | 111 | 969438 | 4094 | 63525089 |
Pulmonary mass | 14.71 | 11.46 | 263 | 969286 | 23753 | 63505430 |
Upper gastrointestinal haemorrhage | 14.71 | 11.46 | 659 | 968890 | 34561 | 63494622 |
Hypermagnesaemia | 14.70 | 11.46 | 43 | 969506 | 1054 | 63528129 |
Orbital oedema | 14.67 | 11.46 | 20 | 969529 | 273 | 63528910 |
Histoplasmosis | 14.66 | 11.46 | 6 | 969543 | 2016 | 63527167 |
Hepatitis C | 14.65 | 11.46 | 101 | 969448 | 10914 | 63518269 |
Ductus arteriosus premature closure | 14.52 | 11.46 | 8 | 969541 | 26 | 63529157 |
Nephrogenic systemic fibrosis | 14.50 | 11.46 | 43 | 969506 | 5849 | 63523334 |
Musculoskeletal disorder | 14.43 | 11.46 | 186 | 969363 | 17720 | 63511463 |
Weight decreased | 14.41 | 11.46 | 3949 | 965600 | 281790 | 63247393 |
Rash macular | 14.41 | 11.46 | 462 | 969087 | 23223 | 63505960 |
Lactic acidosis | 14.40 | 11.46 | 765 | 968784 | 60645 | 63468538 |
Skin cancer | 14.39 | 11.46 | 113 | 969436 | 11861 | 63517322 |
Injury associated with device | 14.37 | 11.46 | 13 | 969536 | 2840 | 63526343 |
Environmental exposure | 14.36 | 11.46 | 22 | 969527 | 336 | 63528847 |
Leukoencephalopathy | 14.31 | 11.46 | 55 | 969494 | 6912 | 63522271 |
Dilatation intrahepatic duct acquired | 14.30 | 11.46 | 32 | 969517 | 662 | 63528521 |
Bilirubin urine present | 14.26 | 11.46 | 21 | 969528 | 309 | 63528874 |
Infusion site bruising | 14.21 | 11.46 | 53 | 969496 | 1479 | 63527704 |
Therapeutic response shortened | 14.07 | 11.46 | 223 | 969326 | 9947 | 63519236 |
Parkinsonism | 14.04 | 11.46 | 143 | 969406 | 14230 | 63514953 |
Device use issue | 14.02 | 11.46 | 5 | 969544 | 1828 | 63527355 |
Gallbladder hypofunction | 13.97 | 11.46 | 25 | 969524 | 437 | 63528746 |
Oral pruritus | 13.96 | 11.46 | 59 | 969490 | 1746 | 63527437 |
Osmolar gap | 13.90 | 11.46 | 14 | 969535 | 135 | 63529048 |
Hypoglycaemic coma | 13.84 | 11.46 | 27 | 969522 | 4247 | 63524936 |
Gene mutation | 13.81 | 11.46 | 7 | 969542 | 2075 | 63527108 |
Intraocular pressure increased | 13.75 | 11.46 | 71 | 969478 | 8231 | 63520952 |
Pulmonary tuberculosis | 13.74 | 11.46 | 59 | 969490 | 7185 | 63521998 |
Caesarean section | 13.73 | 11.46 | 106 | 969443 | 11168 | 63518015 |
Renal cancer | 13.66 | 11.46 | 55 | 969494 | 6820 | 63522363 |
Visual impairment | 13.63 | 11.46 | 944 | 968605 | 73133 | 63456050 |
Toxicologic test abnormal | 13.62 | 11.46 | 45 | 969504 | 1180 | 63528003 |
Blood lactic acid increased | 13.62 | 11.46 | 226 | 969323 | 10175 | 63519008 |
Premature delivery | 13.57 | 11.46 | 197 | 969352 | 18392 | 63510791 |
Complication of device insertion | 13.51 | 11.46 | 35 | 969514 | 4977 | 63524206 |
Dependent personality disorder | 13.50 | 11.46 | 13 | 969536 | 118 | 63529065 |
Haematuria | 13.50 | 11.46 | 757 | 968792 | 59714 | 63469469 |
Choluria | 13.46 | 11.46 | 21 | 969528 | 326 | 63528857 |
Tuberculosis | 13.46 | 11.46 | 128 | 969421 | 12910 | 63516273 |
Erythema multiforme | 13.43 | 11.46 | 320 | 969229 | 15381 | 63513802 |
Acute lymphocytic leukaemia recurrent | 13.42 | 11.46 | 25 | 969524 | 4001 | 63525182 |
Hypothyroidism | 13.42 | 11.46 | 485 | 969064 | 39972 | 63489211 |
Autonomic dysreflexia | 13.33 | 11.46 | 23 | 969526 | 390 | 63528793 |
Haematemesis | 13.32 | 11.46 | 848 | 968701 | 46151 | 63483032 |
Hepatic cancer | 13.32 | 11.46 | 62 | 969487 | 7386 | 63521797 |
SJS-TEN overlap | 13.25 | 11.46 | 25 | 969524 | 456 | 63528727 |
Transverse sinus thrombosis | 13.24 | 11.46 | 29 | 969520 | 591 | 63528592 |
Bone disorder | 13.17 | 11.46 | 175 | 969374 | 16584 | 63512599 |
Knee arthroplasty | 13.16 | 11.46 | 307 | 969242 | 26692 | 63502491 |
Therapeutic product effect decreased | 13.15 | 11.46 | 1525 | 968024 | 113826 | 63415357 |
Strawberry tongue | 13.10 | 11.46 | 7 | 969542 | 21 | 63529162 |
Migraine with aura | 13.08 | 11.46 | 69 | 969480 | 2243 | 63526940 |
Organising pneumonia | 13.07 | 11.46 | 81 | 969468 | 8974 | 63520209 |
Vasoconstriction | 12.99 | 11.46 | 29 | 969520 | 599 | 63528584 |
Diffuse axonal injury | 12.99 | 11.46 | 11 | 969538 | 83 | 63529100 |
Multiple organ dysfunction syndrome | 12.98 | 11.46 | 1330 | 968219 | 100083 | 63429100 |
Obesity | 12.97 | 11.46 | 224 | 969325 | 20338 | 63508845 |
Euglycaemic diabetic ketoacidosis | 12.94 | 11.46 | 40 | 969509 | 5370 | 63523813 |
Device deployment issue | 12.94 | 11.46 | 14 | 969535 | 2812 | 63526371 |
Biliary sepsis | 12.91 | 11.46 | 49 | 969500 | 1379 | 63527804 |
Pancreatic carcinoma | 12.89 | 11.46 | 97 | 969452 | 10276 | 63518907 |
Catheter management | 12.89 | 11.46 | 19 | 969530 | 3336 | 63525847 |
Cyanosis neonatal | 12.88 | 11.46 | 9 | 969540 | 49 | 63529134 |
Blood magnesium increased | 12.87 | 11.46 | 88 | 969461 | 3143 | 63526040 |
Bacterial parotitis | 12.86 | 11.46 | 6 | 969543 | 12 | 63529171 |
Murphy's sign positive | 12.85 | 11.46 | 4 | 969545 | 0 | 63529183 |
Hepatitis non-A non-B | 12.85 | 11.46 | 4 | 969545 | 0 | 63529183 |
Neurone-specific enolase increased | 12.85 | 11.46 | 4 | 969545 | 0 | 63529183 |
Analgesic drug level therapeutic | 12.85 | 11.46 | 4 | 969545 | 0 | 63529183 |
Splenic vein thrombosis | 12.84 | 11.46 | 31 | 969518 | 675 | 63528508 |
Histoplasmosis disseminated | 12.84 | 11.46 | 7 | 969542 | 1991 | 63527192 |
Granulocytopenia | 12.79 | 11.46 | 98 | 969451 | 10342 | 63518841 |
Pneumonia streptococcal | 12.79 | 11.46 | 70 | 969479 | 2308 | 63526875 |
Tardive dyskinesia | 12.79 | 11.46 | 83 | 969466 | 9095 | 63520088 |
Prescribed underdose | 12.78 | 11.46 | 192 | 969357 | 17823 | 63511360 |
Vascular graft | 12.71 | 11.46 | 6 | 969543 | 1853 | 63527330 |
Coagulation factor X level decreased | 12.69 | 11.46 | 11 | 969538 | 86 | 63529097 |
Respiratory tract congestion | 12.63 | 11.46 | 169 | 969380 | 15996 | 63513187 |
Pleural fibrosis | 12.57 | 11.46 | 104 | 969445 | 3946 | 63525237 |
Product tampering | 12.47 | 11.46 | 16 | 969533 | 205 | 63528978 |
Toxoplasmosis | 12.47 | 11.46 | 11 | 969538 | 2433 | 63526750 |
Hypoprothrombinaemia | 12.47 | 11.46 | 31 | 969518 | 688 | 63528495 |
Overflow diarrhoea | 12.47 | 11.46 | 9 | 969540 | 52 | 63529131 |
Malabsorption | 12.45 | 11.46 | 30 | 969519 | 4373 | 63524810 |
Bradycardia neonatal | 12.38 | 11.46 | 10 | 969539 | 70 | 63529113 |
Skin toxicity | 12.38 | 11.46 | 54 | 969495 | 6548 | 63522635 |
Torsade de pointes | 12.33 | 11.46 | 185 | 969364 | 17178 | 63512005 |
Enterococcal infection | 12.33 | 11.46 | 141 | 969408 | 13725 | 63515458 |
Urine bilirubin decreased | 12.32 | 11.46 | 13 | 969536 | 133 | 63529050 |
Arthritis | 12.32 | 11.46 | 1088 | 968461 | 82726 | 63446457 |
Prescription form tampering | 12.30 | 11.46 | 21 | 969528 | 353 | 63528830 |
Left ventricular dysfunction | 12.27 | 11.46 | 180 | 969369 | 16774 | 63512409 |
Stress cardiomyopathy | 12.26 | 11.46 | 85 | 969464 | 9172 | 63520011 |
Urostomy complication | 12.21 | 11.46 | 5 | 969544 | 6 | 63529177 |
Sarcopenia | 12.17 | 11.46 | 21 | 969528 | 356 | 63528827 |
Eosinophil percentage increased | 12.17 | 11.46 | 48 | 969501 | 1376 | 63527807 |
Catatonia | 12.16 | 11.46 | 66 | 969483 | 7554 | 63521629 |
Tendonitis | 12.14 | 11.46 | 223 | 969326 | 20059 | 63509124 |
Chronic graft versus host disease in skin | 12.09 | 11.46 | 3 | 969546 | 1388 | 63527795 |
Herpes zoster | 12.07 | 11.46 | 1025 | 968524 | 78162 | 63451021 |
Respiratory alkalosis | 12.06 | 11.46 | 100 | 969449 | 3797 | 63525386 |
Hyperlipasaemia | 12.05 | 11.46 | 38 | 969511 | 972 | 63528211 |
Thymus disorder | 12.03 | 11.46 | 16 | 969533 | 213 | 63528970 |
Fibrin D dimer increased | 12.02 | 11.46 | 155 | 969394 | 6610 | 63522573 |
Hypertriglyceridaemia | 12 | 11.46 | 109 | 969440 | 11096 | 63518087 |
Open globe injury | 11.96 | 11.46 | 10 | 969539 | 74 | 63529109 |
Type 2 diabetes mellitus | 11.93 | 11.46 | 405 | 969144 | 33615 | 63495568 |
Cyanosis | 11.92 | 11.46 | 426 | 969123 | 21729 | 63507454 |
Tongue disorder | 11.88 | 11.46 | 120 | 969429 | 11960 | 63517223 |
Cerebral haemorrhage | 11.88 | 11.46 | 637 | 968912 | 50453 | 63478730 |
Enanthema | 11.87 | 11.46 | 31 | 969518 | 710 | 63528473 |
Polycystic ovaries | 11.87 | 11.46 | 9 | 969540 | 2146 | 63527037 |
Skin ulcer | 11.83 | 11.46 | 540 | 969009 | 43434 | 63485749 |
Congestive cardiomyopathy | 11.80 | 11.46 | 99 | 969450 | 10245 | 63518938 |
Generalised bullous fixed drug eruption | 11.79 | 11.46 | 5 | 969544 | 7 | 63529176 |
Visceral congestion | 11.77 | 11.46 | 33 | 969516 | 789 | 63528394 |
Delusion | 11.77 | 11.46 | 195 | 969354 | 17819 | 63511364 |
Osmolar gap abnormal | 11.75 | 11.46 | 10 | 969539 | 76 | 63529107 |
Catheterisation cardiac | 11.68 | 11.46 | 36 | 969513 | 4837 | 63524346 |
Cardiac steatosis | 11.67 | 11.46 | 8 | 969541 | 42 | 63529141 |
Periportal oedema | 11.67 | 11.46 | 11 | 969538 | 97 | 63529086 |
Nasopharyngitis | 11.66 | 11.46 | 3213 | 966336 | 192860 | 63336323 |
Anxiety | 11.65 | 11.46 | 3316 | 966233 | 199333 | 63329850 |
Paranoid personality disorder | 11.64 | 11.46 | 7 | 969542 | 28 | 63529155 |
Exercise tolerance decreased | 11.64 | 11.46 | 68 | 969481 | 7642 | 63521541 |
Pneumocystis jirovecii infection | 11.61 | 11.46 | 11 | 969538 | 2350 | 63526833 |
Metabolic disorder | 11.56 | 11.46 | 68 | 969481 | 7629 | 63521554 |
Lupus vulgaris | 11.55 | 11.46 | 10 | 969539 | 78 | 63529105 |
Drug effective for unapproved indication | 11.52 | 11.46 | 24 | 969525 | 3684 | 63525499 |
Congenital central hypoventilation syndrome | 11.46 | 11.46 | 7 | 969542 | 29 | 63529154 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Accidental overdose | 30.77 | 14.82 | 17 | 863 | 89 | 83709 |
Analgesic drug level increased | 25.07 | 14.82 | 7 | 873 | 0 | 83798 |
Overdose | 16.73 | 14.82 | 9 | 871 | 44 | 83754 |
Source | Code | Description |
---|---|---|
ATC | N02AJ01 | NERVOUS SYSTEM ANALGESICS OPIOIDS Opioids in combination with non-opioid analgesics |
ATC | N02AJ06 | NERVOUS SYSTEM ANALGESICS OPIOIDS Opioids in combination with non-opioid analgesics |
ATC | N02AJ13 | NERVOUS SYSTEM ANALGESICS OPIOIDS Opioids in combination with non-opioid analgesics |
ATC | N02AJ17 | NERVOUS SYSTEM ANALGESICS OPIOIDS Opioids in combination with non-opioid analgesics |
ATC | N02BE01 | NERVOUS SYSTEM ANALGESICS OTHER ANALGESICS AND ANTIPYRETICS Anilides |
ATC | N02BE51 | NERVOUS SYSTEM ANALGESICS OTHER ANALGESICS AND ANTIPYRETICS Anilides |
ATC | N02BE71 | NERVOUS SYSTEM ANALGESICS OTHER ANALGESICS AND ANTIPYRETICS Anilides |
MeSH PA | D000700 | Analgesics |
MeSH PA | D018712 | Analgesics, Non-Narcotic |
MeSH PA | D058633 | Antipyretics |
MeSH PA | D002491 | Central Nervous System Agents |
MeSH PA | D018373 | Peripheral Nervous System Agents |
MeSH PA | D018689 | Sensory System Agents |
CHEBI has role | CHEBI:35475 | non-steroidal anti-inflammatory agent |
CHEBI has role | CHEBI:35493 | anti-pyretic |
CHEBI has role | CHEBI:35703 | Xenobiotic |
CHEBI has role | CHEBI:50629 | COX-2 inhibitor |
CHEBI has role | CHEBI:50630 | COX-1 inhibitor |
CHEBI has role | CHEBI:50908 | agente hepatotoxico |
CHEBI has role | CHEBI:73263 | cyclooxygenase-3 inhibitors |
CHEBI has role | CHEBI:78298 | environmental contaminants |
CHEBI has role | CHEBI:85234 | human blood serum metabolites |
CHEBI has role | CHEBI:173085 | ferroptosis inducers |
CHEBI has role | CHEBI:176497 | geroprotectors |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Sinus headache | indication | 4969004 | |
Pain | indication | 22253000 | |
Toothache | indication | 27355003 | |
Migraine | indication | 37796009 | DOID:6364 |
Joint pain | indication | 57676002 | |
Allergic rhinitis | indication | 61582004 | |
Common cold | indication | 82272006 | DOID:10459 |
Backache | indication | 161891005 | |
Headache disorder | indication | 230461009 | |
Influenza-like symptoms | indication | 315642008 | |
Fever | indication | 386661006 | |
Tension-type headache | indication | 398057008 | |
Arthritic Pain | indication | ||
Pain Treatment Adjunct | indication | ||
Vascular headache | off-label use | 128187005 | |
Fibromyalgia | off-label use | 203082005 | DOID:631 |
Hepatic encephalopathy | contraindication | 13920009 | DOID:13413 |
Cirrhosis of liver | contraindication | 19943007 | DOID:5082 |
Hepatic failure | contraindication | 59927004 | |
Disease of liver | contraindication | 235856003 | DOID:409 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 9.69 | acidic |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
325MG;7.5MG | XARTEMIS XR | MALLINCKRODT INC | N204031 | March 11, 2014 | DISCN | TABLET, EXTENDED RELEASE | ORAL | 7976870 | June 1, 2027 | METHOD OF TREATING PATIENTS WITH GASTRIC RETENTIVE DOSAGE FORM |
1GM/100ML (10MG/ML) | OFIRMEV | MALLINCKRODT HOSP | N022450 | Nov. 2, 2010 | DISCN | SOLUTION | INTRAVENOUS | 10383834 | Nov. 13, 2028 | MODIFIED DOSING REGIMEN FOR THE MANAGEMENT OF MILD TO MODERATE PAIN |
1GM/100ML (10MG/ML) | OFIRMEV | MALLINCKRODT HOSP | N022450 | Nov. 2, 2010 | DISCN | SOLUTION | INTRAVENOUS | 10383834 | Nov. 13, 2028 | MODIFIED DOSING REGIMEN FOR THE REDUCTION OF FEVER |
1GM/100ML (10MG/ML) | OFIRMEV | MALLINCKRODT HOSP | N022450 | Nov. 2, 2010 | DISCN | SOLUTION | INTRAVENOUS | 9610265 | Nov. 13, 2028 | MODIFIED DOSING REGIMEN FOR THE MANAGEMENT OF MODERATE TO SEVERE PAIN WITH ADJUNCTIVE OPIOID ANALGESICS |
1GM/100ML (10MG/ML) | OFIRMEV | MALLINCKRODT HOSP | N022450 | Nov. 2, 2010 | DISCN | SOLUTION | INTRAVENOUS | 9987238 | Nov. 13, 2028 | MODIFIED DOSING REGIMEN FOR THE MANAGEMENT OF MILD TO MODERATE PAIN OR MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADJUNCT TO OPIOID ANALGESICS |
325MG;7.5MG | XARTEMIS XR | MALLINCKRODT INC | N204031 | March 11, 2014 | DISCN | TABLET, EXTENDED RELEASE | ORAL | 8372432 | March 11, 2029 | MANAGEMENT OF ACUTE PAIN IN PATIENTS REQUIRING OPIOID ANALGESIA |
325MG;7.5MG | XARTEMIS XR | MALLINCKRODT INC | N204031 | March 11, 2014 | DISCN | TABLET, EXTENDED RELEASE | ORAL | 8668929 | March 11, 2029 | MANAGEMENT OF ACUTE PAIN IN PATIENTS REQUIRING OPIOID ANALGESIA |
325MG;7.5MG | XARTEMIS XR | MALLINCKRODT INC | N204031 | March 11, 2014 | DISCN | TABLET, EXTENDED RELEASE | ORAL | 8377453 | Nov. 19, 2029 | MANAGEMENT OF ACUTE PAIN IN PATIENTS REQUIRING OPIOID ANALGESIA |
325MG;EQ 4.08MG BASE | APADAZ | KVK TECH INC | N208653 | Jan. 4, 2019 | RX | TABLET | ORAL | 9132125 | July 1, 2030 | MANAGEMENT OF ACUTE PAIN SEVERE ENOUGH TO REQUIRE AN OPIOID ANALGESIC AND FOR WHICH ALTERNATIVE TREATMENTS ARE INADEQUATE |
325MG;EQ 6.12MG BASE | APADAZ | KVK TECH INC | N208653 | Feb. 23, 2018 | RX | TABLET | ORAL | 9132125 | July 1, 2030 | MANAGEMENT OF ACUTE PAIN SEVERE ENOUGH TO REQUIRE AN OPIOID ANALGESIC AND FOR WHICH ALTERNATIVE TREATMENTS ARE INADEQUATE |
325MG;EQ 8.16MG BASE | APADAZ | KVK TECH INC | N208653 | Jan. 4, 2019 | RX | TABLET | ORAL | 9132125 | July 1, 2030 | MANAGEMENT OF ACUTE PAIN SEVERE ENOUGH TO REQUIRE AN OPIOID ANALGESIC AND FOR WHICH ALTERNATIVE TREATMENTS ARE INADEQUATE |
1GM/100ML (10MG/ML) | OFIRMEV | MALLINCKRODT HOSP | N022450 | Nov. 2, 2010 | DISCN | SOLUTION | INTRAVENOUS | 9399012 | Sept. 11, 2031 | MODIFIED DOSING REGIMEN FOR THE MANAGEMENT OF MILD TO MODERATE PAIN OR MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADJUNCT TO OPIOID ANALGESICS |
1GM/100ML (10MG/ML) | OFIRMEV | MALLINCKRODT HOSP | N022450 | Nov. 2, 2010 | DISCN | SOLUTION | INTRAVENOUS | 9399012 | Sept. 11, 2031 | MODIFIED DOSING REGIMEN FOR THE REDUCTION OF FEVER |
325MG;7.5MG | XARTEMIS XR | MALLINCKRODT INC | N204031 | March 11, 2014 | DISCN | TABLET, EXTENDED RELEASE | ORAL | 8741885 | May 16, 2032 | MANAGEMENT OF ACUTE PAIN IN PATIENTS REQUIRING OPIOID ANALGESIA |
325MG;7.5MG | XARTEMIS XR | MALLINCKRODT INC | N204031 | March 11, 2014 | DISCN | TABLET, EXTENDED RELEASE | ORAL | 9468636 | May 16, 2032 | MANAGEMENT OF ACUTE PAIN IN PATIENTS REQUIRING OPIOID ANALGESIA |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
---|---|---|---|---|---|---|---|---|---|
250MG;125MG | ADVIL DUAL ACTION WITH ACETAMINOPHEN | GLAXOSMITHKLINE | N211733 | Feb. 28, 2020 | OTC | TABLET | ORAL | Feb. 28, 2023 | NEW PRODUCT |
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Prostaglandin G/H synthase 2 | Enzyme | INHIBITOR | IC50 | 4.31 | WOMBAT-PK | CHEMBL | |||
Transient receptor potential cation channel subfamily V member 1 | Ion channel | OPENER | WOMBAT-PK | CHEMBL | |||||
Cannabinoid receptor 1 | GPCR | AGONIST | WOMBAT-PK | SCIENTIFIC LITERATURE | |||||
Carbonic anhydrase 2 | Enzyme | Ki | 5.21 | CHEMBL | |||||
Carbonic anhydrase 1 | Enzyme | Ki | 5 | CHEMBL | |||||
Carbonic anhydrase 4 | Enzyme | Ki | 4.94 | CHEMBL | |||||
Carbonic anhydrase 9 | Enzyme | Ki | 4.15 | CHEMBL | |||||
Carbonic anhydrase 12 | Enzyme | Ki | 5.39 | CHEMBL | |||||
Carbonic anhydrase 7 | Enzyme | Ki | 5.04 | CHEMBL | |||||
Carbonic anhydrase 3 | Enzyme | Ki | 5.15 | CHEMBL | |||||
Carbonic anhydrase 14 | Enzyme | Ki | 4.97 | CHEMBL | |||||
Arachidonate 5-lipoxygenase-activating protein | Cytosolic other | IC50 | 4.36 | CHEMBL | |||||
Myoglobin | Unclassified | IC50 | 5.64 | CHEMBL | |||||
Nuclear receptor subfamily 1 group I member 3 | Nuclear hormone receptor | WOMBAT-PK | |||||||
Arachidonate 15-lipoxygenase | Enzyme | IC50 | 4.55 | DRUG MATRIX | |||||
Carbonic anhydrase 13 | Enzyme | Ki | 4.52 | CHEMBL | |||||
Carbonic anhydrase 15 | Enzyme | Ki | 5.03 | CHEMBL |
ID | Source |
---|---|
4017513 | VUID |
N0000145898 | NUI |
D00217 | KEGG_DRUG |
161 | RXNORM |
C0000970 | UMLSCUI |
CHEBI:46195 | CHEBI |
NNS | PDB_CHEM_ID |
CHEMBL112 | ChEMBL_ID |
DB00316 | DRUGBANK_ID |
5239 | IUPHAR_LIGAND_ID |
362O9ITL9D | UNII |
1983 | PUBCHEM_CID |
4119 | MMSL |
4973 | MMSL |
4992 | MMSL |
5005 | MMSL |
52845 | MMSL |
97317 | MMSL |
d00049 | MMSL |
001605 | NDDF |
4017513 | VANDF |
D000082 | MESH_DESCRIPTOR_UI |
626 | INN_ID |
387517004 | SNOMEDCT_US |
90332006 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Childrens Dimetapp Multi-Symptom Cold and Flu | HUMAN OTC DRUG LABEL | 3 | 0031-2249 | LIQUID | 320 mg | ORAL | Unapproved drug other | 17 sections |
Robitussin Maximum Strength Severe Multi-Symptom 7 in 1 Relief Nighttime | HUMAN OTC DRUG LABEL | 3 | 0031-8744 | CAPSULE, LIQUID FILLED | 325 mg | ORAL | OTC MONOGRAPH FINAL | 17 sections |
Robitussin Maximum Strength Severe Cough Plus Sore Throat | HUMAN OTC DRUG LABEL | 2 | 0031-8750 | LIQUID | 650 mg | ORAL | OTC monograph final | 17 sections |
Robitussin Severe Multi-Symptom Cough Cold Flu | HUMAN OTC DRUG LABEL | 4 | 0031-8751 | LIQUID | 650 mg | ORAL | OTC monograph final | 17 sections |
Robitussin Severe Multi-Symptom Cough Cold Flu Nighttime | HUMAN OTC DRUG LABEL | 3 | 0031-8752 | SOLUTION | 650 mg | ORAL | OTC monograph final | 17 sections |
Robitussin Severe Multi-Symptom Cough Cold Flu Nighttime | HUMAN OTC DRUG LABEL | 3 | 0031-8752 | SOLUTION | 650 mg | ORAL | OTC monograph final | 17 sections |
Robitussin Honey Severe Cough, Flu Plus Sore Throat Nighttime | HUMAN OTC DRUG LABEL | 2 | 0031-8770 | SOLUTION | 650 mg | ORAL | OTC MONOGRAPH FINAL | 17 sections |
Robitussin Honey Severe Cough, Flu Plus Sore Throat | HUMAN OTC DRUG LABEL | 2 | 0031-8771 | SOLUTION | 650 mg | ORAL | OTC MONOGRAPH FINAL | 17 sections |
Butalbital, Acetaminophen, Caffeine and Codeine Phosphate | HUMAN PRESCRIPTION DRUG LABEL | 4 | 0054-0650 | CAPSULE | 300 mg | ORAL | ANDA | 33 sections |
Butalbital, Acetaminophen, Caffeine and Codeine Phosphate | HUMAN PRESCRIPTION DRUG LABEL | 4 | 0054-3000 | CAPSULE | 325 mg | ORAL | ANDA | 33 sections |
Roxicet | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0054-3686 | SOLUTION | 325 mg | ORAL | ANDA | 23 sections |
Roxicet | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0054-4650 | TABLET | 325 mg | ORAL | ANDA | 23 sections |
Roxicet | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0054-8648 | SOLUTION | 325 mg | ORAL | ANDA | 23 sections |
Roxicet | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0054-8650 | TABLET | 325 mg | ORAL | ANDA | 23 sections |
TheraFlu Cold and Flu | HUMAN OTC DRUG LABEL | 3 | 0067-0924 | POWDER | 325 mg | ORAL | Export only | 10 sections |
ExcedrinExtra Strength Pain Reliever | HUMAN OTC DRUG LABEL | 3 | 0067-2000 | TABLET, FILM COATED | 250 mg | ORAL | OTC monograph not final | 13 sections |
ExcedrinExtra Strength Pain Reliever | HUMAN OTC DRUG LABEL | 3 | 0067-2001 | TABLET, FILM COATED | 250 mg | ORAL | OTC monograph not final | 15 sections |
ExcedrinExtra Strength Geltabs | HUMAN OTC DRUG LABEL | 3 | 0067-2021 | TABLET, COATED | 250 mg | ORAL | OTC monograph not final | 14 sections |
ExcedrinMigraine Geltabs | HUMAN OTC DRUG LABEL | 3 | 0067-2035 | TABLET, COATED | 250 mg | ORAL | NDA | 14 sections |
EXCEDRINMIGRAINE | HUMAN OTC DRUG LABEL | 3 | 0067-2039 | TABLET, FILM COATED | 250 mg | ORAL | NDA | 15 sections |
ExcedrinMigraine | HUMAN OTC DRUG LABEL | 3 | 0067-2040 | TABLET, FILM COATED | 250 mg | ORAL | NDA | 16 sections |
Excedrin PM Triple Action Caplets | HUMAN OTC DRUG LABEL | 3 | 0067-2056 | TABLET, COATED | 250 mg | ORAL | OTC monograph not final | 16 sections |
TherafluPowerPods Daytime Severe Cold | HUMAN OTC DRUG LABEL | 3 | 0067-6094 | POWDER, FOR SOLUTION | 650 mg | ORAL | OTC monograph final | 16 sections |
THERAFLUPOWERPODS NIGHTTIME SEVERE COLD | HUMAN OTC DRUG LABEL | 3 | 0067-6095 | POWDER, FOR SOLUTION | 650 mg | ORAL | OTC monograph final | 16 sections |
THERAFLUMULTI-SYMPTOM SEVERE COLD | HUMAN OTC DRUG LABEL | 3 | 0067-6426 | POWDER, FOR SOLUTION | 500 mg | ORAL | OTC monograph final | 17 sections |
TherafluFlu and Sore Throat | HUMAN OTC DRUG LABEL | 3 | 0067-7916 | POWDER, FOR SOLUTION | 650 mg | ORAL | OTC monograph final | 17 sections |
TherafluDaytime Severe Cold and Cough | HUMAN OTC DRUG LABEL | 3 | 0067-7917 | POWDER, FOR SOLUTION | 650 mg | ORAL | OTC monograph final | 16 sections |
THERAFLUNIGHTTIME SEVERE COLD AND COUGH | HUMAN OTC DRUG LABEL | 3 | 0067-7918 | POWDER, FOR SOLUTION | 650 mg | ORAL | OTC monograph final | 17 sections |
THERAFLUSINUS AND PAIN | HUMAN OTC DRUG LABEL | 3 | 0067-7920 | POWDER, FOR SOLUTION | 650 mg | ORAL | OTC monograph final | 17 sections |
THERAFLUSINUS AND PAIN | HUMAN OTC DRUG LABEL | 3 | 0067-7920 | POWDER, FOR SOLUTION | 650 mg | ORAL | OTC monograph final | 17 sections |